Solvency and Financial Condition Report

Reporting Year 2025

eurolife

eurolife

SOLVENCY AND FINANCIAL CONDITION REPORT

EUROLIFE LTD

FOR THE YEAR ENDED

31 DECEMBER 2025

(RE-ISSUED)

Table of Contents

1. Executive Summary 5

1.1 Overview 5

1.2 Business and performance 6

1.3 System of Governance 6

1.4 Risk profile 6

1.5 Valuation for solvency purposes 8

1.6 Capital Management 8

A. Business and performance 10

A.1 Business 10

A.2 Underwriting performance 10

A.3 Investment performance 11

A.4 Other 15

B. System of Governance 17

B.1 General information on the System of Governance 17

B.1.1 Roles & Responsibilities of the Board, Senior Management and Key Functions 17

B.1.2 Material changes in the system of governance during 2025 21

B.1.3 Remuneration Policy and Practices 21

B.1.4 Material Transactions during 2025 22

B.2 Fit and Proper Requirements 22

B.2.1 Requirements for skills, knowledge and expertise 22

B.2.2 Fit and proper assessment process 22

B.3 Risk Management System and ORSA process 23

B.3.1 Risk Management System 23

B.3.2 ORSA process 24

B.4 Internal Control System 24

B.4.1 Description of the Internal Control System 25

B.4.2 Implementation of the Compliance Function 26

B.5 Internal Audit Function 27

B.5.1 Implementation of the Internal Audit Function 27

B.5.2 Independence of the Internal Audit Function 27

B.6 Actuarial Function 27

B.7 Information Security Function 27

B.8 Outsourcing 28

B.9 Adequacy of the system of governance 28

C. Risk Profile **31**

C.1 Underwriting Risk 31

C.2 Market Risk 34

C.3 Credit Risk 35

C.4 Liquidity Risk 36

C.5 Operational Risk 37

C.6 Other Material Risks 38

C.7 Other information 38

D. Valuation for Solvency purposes **40**

D.1 Assets 40

D.2 Technical Provisions 42

D.3 Liabilities (other than technical provisions) 44

D.4 Other 45

E. Capital Management **47**

E.1 Own Funds 47

E.2 Solvency Capital Requirement and Minimum Capital Requirement 48

E.3 Non-Compliance with the MCR and Non-Compliance with the SCR 49

E.4 Other 49

F. Glossary **51**

G.Templates **52**

H. Independent Auditors Report **55**

1. Executive Summary

1. Executive Summary

1.1 Overview

Eurolife Limited ("the Company") is incorporated in Cyprus and is a company limited by shares. The Company operates predominantly in Cyprus and is a 100% subsidiary of the Bank of Cyprus (BoC) Group. The Company offers individual unit-linked products and simple-term cover products, as well as individual accident and health products. It also offers life and accident cover on a group basis. Finally, the Company offers provision of services for administering Occupational Pension Scheme assets.

Acquisition and Merger of Ethniki Insurance (Cyprus) Ltd

In April 2025, Bank of Cyprus Public Company Limited announced a binding agreement for the acquisition of Ethniki Insurance (Cyprus) Ltd. In July 2025, following the completion of all required regulatory approvals, Bank of Cyprus Public Company Limited completed the acquisition of a 100% interest in Ethniki Insurance (Cyprus) Ltd. Ethniki Insurance (Cyprus) Ltd was the parent entity of Ethniki General Insurance Cyprus Ltd, and together they operated under the trade name Ethniki Insurance Cyprus, an established provider in both the life and non-life insurance sectors in Cyprus.

On 23 December 2025, following the issuance of a court ruling and after securing all necessary approvals under the Cyprus Companies Law and the Cyprus Insurance and Reinsurance Services and Other Related Issues Law, the Company acquired the entire business, assets and liabilities of Ethniki Insurance (Cyprus) Ltd, and additionally acquired a portfolio of health insurance contracts from Ethniki General Insurance Cyprus Ltd.

System of Governance, Strategy and Competitive Environment

The Company has established a system of governance designed to ensure the sound and prudent management of its business. The governance framework includes a transparent organisational structure with a clear allocation of responsibilities and appropriate segregation of duties.

The Company has a solid strategy in place to face competitive challenges. Emphasis is given on improving the existing product offering to secure competitiveness, upgrading customer experience, digital transformation initiatives and safeguarding efficient cost management.

The Company's Board and Management actively monitor the competitive environment and take appropriate measures to safeguard service excellence and protect the interests of our customers.

Distribution Channels

The Company distributes its products primarily through an exclusive tied agency network, operating via branch facilities located in Nicosia, Limassol, Larnaca, Paralimni and Paphos. In addition, a tied agency agreement with Bank of Cyprus has been in place since 2006 for the provision of insurance intermediation services. The Company may also distribute its products directly to customers.

Purpose of the Report

The purpose of the Solvency and Financial Condition Report (SFCR) is to satisfy the public disclosure requirements under article 304(1) of the Delegated Regulation (EU) 2015/35. The elements of the disclosure relate to business performance, governance, risk profile, valuation for solvency purposes and capital management. The SFCR has been prepared with reference date 31 December 2025.

The Company has, at all times since the initial implementation of Solvency II on 1 January 2016, fully complied with all applicable regulatory requirements.

According to article 74(2) of the Law on Insurance and Reinsurance Services and Other Related Business of 2016, the independent auditors of the Company audit certain information which is defined in the "Orders of the Superintendent of Insurance in relation to the annual audit of the Solvency and Financial Condition Report" and they submit a separate report in relation to it on the date of submission of the SFCR. The Report is published on the Company's website at www.eurolife.com.cy.

Key figures – 31 December 2025

- €926 million Assets Under Management
- €258 million Total Income
- €225 million Regular Income
- More than €100 million Total Claims Paid
- 226% Solvency II ratio
- 32,9% market share in Life and Health regular income

1.2 Business and performance

The Company prepares its financial statements in accordance with International Financial Reporting Standards (IFRS). On an IFRS basis the Company had an after-tax underwriting profit of €34,4m. The Company's assets are prudently invested, considering the liquidity requirements of the business and the timing of the insurance liabilities.

1.3 System of Governance

The Board of Directors (BoD/Board) of the Company is committed to good governance which is vital to creating trust and engagement between the Company and its stakeholders and contributes towards its long-term success. A key objective of the governance framework of the Company is to ensure compliance with applicable legal and regulatory requirements and based on best practices of corporate governance and corporate administration.

The Company aims, on an ongoing basis, to operate as a modern, transparent and competitive organisation. Through the adoption of best practices, the Company promotes effective and constructive communication with the Board, Management and its shareholder, supporting the successful implementation of its strategy and a robust corporate governance framework.

The Board of Directors has overall responsibility for the management of the Company, and ultimate oversight of its operations. At the end of 2025, the Board consisted of 7 members, of which 4 were Independent Non-Executive Directors, and 3 were Executive Directors.

The Company's Board monitors the performance of Senior Management and gives guidance and advice, where appropriate. To strengthen its internal control system, the Company has set up the following internal control functions, in accordance with Solvency II requirements:

- Risk Management Function
- Actuarial Function
- Compliance Function
- Information Security Function
- Internal Audit Function (outsourced to the BoC Group).

During the year 2025, the following changes occurred in the Company's system of governance:

- The Executive Chairman of the Board served until 18/11/2025. On the same date, a newly appointed Independent NED was appointed and assumed the position of Chairman.
- The Company appointed three new Independent NEDs on 18/11/2025.
- The two previous Independent NEDs resigned on 18/11/2025.
- One Executive Member resigned on 18/06/2025.
- Two non-independent, non-executive Members resigned on 18/11/2025.
- Effective July 2025 and following the formal approval of the Audit Committee and the Board of Directors, the Legal & Compliance Function was restructured into two separate units to enhance governance and strengthen compliance oversight.
- The Company changed its organisational structure in December 2025, effective from 1 January 2026 with no impact on the reporting lines or the independence of its control functions; the only change related to the separation of the Actuarial Function and the Risk Management Function into two distinct units.

No other changes have taken place within 2025.

1.4 Risk profile

A key component of the risk management system and the Own Risk and Solvency Assessment (ORSA) process is the annual risk assessment exercise, through which the Company assesses its position regarding the different risks to which it is or might be exposed. The assessment covers all risk types, including less-quantifiable risks, and aims to determine the Company's risk profile taking into consideration its risk appetite. It is based on quantitative and qualitative criteria, prior experience and expert judgment.

As part of the ORSA process, the Company performs stress tests on material risks using some common and some extreme but plausible scenarios to examine the impact on its future capital and solvency position. The purpose of this exercise is to identify whether the Company will remain solvent and adequately capitalised should any of these tests or scenarios materialise.

The main results of the risk assessment and ORSA process performed in 2025 are summarized below:

- Market risk was considered material due to the significant exposures to Bond Funds. The 2025 ORSA stress testing, including the combined economic downturn scenario with mass lapse events, confirmed that the Company's solvency ratio remains well above the minimum regulatory requirements. Close monitoring of exposures to Bond Funds will continue, and strategic priorities might be revised to enhance growth initiatives, allowing for the prevailing economic conditions.
- Operational risk was also considered as a material risk. As part of the ORSA process, stress test scenarios were carried out combining multiple factors, including the materialisation of operational risk events. The solvency ratio remained well above the regulatory limit. In addition, relevant mitigating actions were approved by the Board during the review and approval of the ORSA Report for 2025.
- Business risk was assessed as a material risk for the Company during 2025. As part of the ORSA process, stress testing included business risk-related shocks, indicating that the Company's solvency ratio would remain well above the regulatory limit. Necessary actions shall be taken as necessary to secure competitiveness based on market conditions.
- Underwriting and Liquidity risks were also taken into consideration when carrying out the stress test scenarios during the ORSA process.

1.5 Valuation for solvency purposes

The valuation of assets and liabilities for Solvency II purposes is the same as IFRS except:

- Differences in some of the assumptions used for the calculation of technical provisions and associated reinsurance recoverables.
- Assets under IFRS include intangibles, which are valued at zero under Solvency II.
- The Solvency II balance sheet includes a deferred tax liability arising on reporting differences from the change in technical provisions under Solvency II.

These differences are summarized below:

	31.12.2025	31.12.2024
	€'000	€'000
Total own funds per Financial Statements	**144.427**	**114.312**
Intangible assets	(7.988)	(6.388)
Change in valuation of Technical Provisions (net)	18.732	6.225
Change in Deferred Tax Liability	(2.810)	(778)
Total own funds per Solvency II	**152.361**	**113.371**

1.6 Capital Management

During 2026, the Company identified parameterisation errors affecting the lapse, expense and morbidity stress calculations. The SCR Model review further identified that the effect of reinsurance as a risk mitigation technique had not been reflected in the calculation of Life and Health Underwriting Risks.

The relevant calculations were corrected, and the Company's solvency position has been recalculated accordingly. The Solvency Ratio as at 31 December 2025 was revised to 226%, compared with the previously reported 281%, while the Solvency Ratio as at 31 December 2024 was revised to 224%, compared with the previously reported 226%.

To ensure the stakeholders have access to accurate and up-to-date information, the Company has reissued this SFCR, subsequent to its submission on 3 April 2026 and 13 August 2026 to provide enhanced disclosures in relation to this matter (including comparatives figures for 2024).

The revision did not affect the Company's compliance with regulatory capital requirements, as the Solvency Ratio remained comfortably above the applicable regulatory minimum requirement of 100%. The Superintendent of Insurance was informed of the matter and imposed an administrative fine of €100.000.

The Company has undertaken a number of corrective and preventive measures to remedy the issue identified, reinforce the accuracy and reliability of its models and mitigate the risk of similar issues arising in the future. In addition, the Company is taking further steps to strengthen its model review, validation and monitoring processes while embedding enhancements across its broader control framework.

The revised Solvency coverage ratio at 31 December 2025 is 226% with own funds of €152,4m, a Solvency Capital Requirement (SCR) of €67,5m and a Minimum Capital Requirement (MCR) of €23,8m. The final amount of the SCR and MCR remains subject to supervisory assessment.

The objective of own funds management is to maintain, at all times, sufficient own funds to cover the SCR and MCR with an appropriate buffer. The Company has maintained sufficient capital to meet its MCR and SCR throughout the year 2025.

A. Business and performance

A. Business and performance

A.1 Business

Eurolife Limited ("the Company") is incorporated in Cyprus and is a company limited by shares. The address of its registered office is 4 Evrou street, Strovolos, P.O. Box 2003, Nicosia, Cyprus. This Solvency and Financial Condition Report (SFCR) covers Eurolife Limited.

The Company is regulated by the Insurance Companies Control Service (ICCS) in Cyprus. The independent auditors of the Company is PricewaterhouseCoopers Limited, Certified Public Accountants and Registered Auditors.

The Company is a 100% subsidiary of the Bank of Cyprus (BoC) Group. From 18 January 2017, Bank of Cyprus Holdings Public Limited Company became the sole shareholder of the Bank of Cyprus Public Company Ltd. Further information on the BoC Group can be found in its consolidated financial statements published on the BoC website at www.bankofcyprus.com.

The Company offers individual unit-linked products and simple-term cover products, as well as individual accident and health products. It also offers life and accident cover on a group basis. The Company provides services for the administration of Occupational Pension Scheme assets. The Company prepares its financial statements in accordance with IFRS Accounting Standards as adopted by the European Union. Under IFRS (and for management reporting purposes), the business is divided into Life, Health and Occupational Pensions.

In April 2025, Bank of Cyprus Public Company Limited announced that it had reached a binding agreement for the acquisition of Ethniki Insurance (Cyprus) Ltd. In July 2025, following the completion of all required regulatory approvals, Bank of Cyprus Public Company Limited completed the acquisition of a 100% interest in Ethniki Insurance (Cyprus) Ltd. Ethniki Insurance (Cyprus) Ltd was the parent entity of Ethniki General Insurance Cyprus Ltd, and together they operated under the trade name Ethniki Insurance Cyprus, an established provider in both the life and non-life insurance sectors in Cyprus.

On 23 December 2025, following the issuance of a court ruling and after securing all necessary approvals under the Cyprus Companies Law and the Cyprus Insurance and Reinsurance Services and Other Related Issues Law, the Company acquired the entire business, assets and liabilities of Ethniki Insurance (Cyprus) Ltd, and additionally acquired a portfolio of health insurance contracts from Ethniki General Insurance Cyprus Ltd.

As a result, the Company is the merged entity, and this SFCR for the year ended 31 December 2025 (comparatives relate to Eurolife only) reflects the activities, performance and financial position of the Company after the full operational and legal merger of the above businesses, in line with Solvency II disclosure requirements for solo entities.

For Solvency II purposes the following lines are used:

- Health insurance:
  - Non-SLT Health (Similar to non-Life Techniques)
  - SLT Health obligations (Similar to Life Techniques)
- Index-linked and unit-linked insurance: Insurance obligations with index-linked and unit-linked features
- Insurance with profit participation
- Other life insurance

These Solvency II lines of business are used when reporting the premium, claims, expenses and technical provisions in the Solvency II Quantitative Reporting Templates (QRTs).

The Company engages in the business of life, health and occupational pensions in Cyprus. In Greece, the Company was operating through a branch under the name of Kyprou Zois which remained dormant.

Other than the above, no significant events occurred during the reporting period that had a material impact on the business or performance of the Company.

A.2 Underwriting performance

Since the Company prepares its financial statements in accordance with IFRS Accounting Standards as adopted by the European Union, the underwriting performance information given in this section is also provided on an IFRS Accounting Standards basis as adopted by the European Union.

The table below shows the underwriting performance per material line of business:

Underwriting performance	2025	2024
	€'000	€'000
Underwriting performance – Individual life	24.631	18.991
Underwriting performance – Health and Group life business	9.397	6.468
Underwriting performance – Investment contracts	380	(531)
Total net underwriting performance (based on IFRS)	**34.408**	**24.928**

The 2025 results have been mainly affected by the following:

- Positive one-off impact from the abolishment of premium tax.
- Positive impact from the change in actuarial assumptions.
- Negative impact from reinsurance service result measured under GMM due to less favourable claims experience as well as the impact from the aforementioned change in actuarial assumptions.

A.3 Investment performance

Since the Company prepares its financial statements in accordance with IFRS Accounting Standards as adopted by the European Union, the investment performance information provided in this section is on an IFRS Accounting Standards basis as adopted by the European Union.

Unit-linked assets:

The composition of the unit-linked assets and information on income and expenses arising from investments by asset class are shown below:

Asset class	Position as at 31.12.2025	Income/gains and losses - 2025	Position as at 31.12.2025 – Ex Ethniki	Position as at 31.12.2024	Income/gains and losses - 2024
	%	€'000	%	%	€'000
Government Bonds	7,61	3.440	42,07	8,07	1.798
Corporate Bonds	2,31	447	0,31	2,57	(780)
Equity instruments	0,19	953	3,43	0,28	824
Cash and deposits	2,34	127	30,87	3,90	218
Mortgages and loans	0,03	12	-	0,05	16
Properties	1,30	10	-	1,52	360
Collective investments undertakings	86,22	33.116	23,32	83,61	65.323
	100,00	**38.105**	**100,00**	**100,00**	**67.759**

The tables below show the composition of unit-linked assets and annualised returns for 2025 and 2024 (net of fees) as disclosed in policyholder literature:

Asset class – Eurolife funds	Balanced Fund	Guaranteed Fund	Income Fund	Growth Fund	Manulife Investment Fund	GIC Investors Fund	Conservative Fund	Level Up CY30 Fund	Level Up CY30/2 Fund	Level Up CY33 Fund	Level Up CY33/2 Fund	LEVEL- UP CY33/3
31.12.2025	%	%	%	%	%	%	%	%	%	%	%	%
Local equities and equity funds	0,28	-	-	-	0,28	0,28	-	-	-	-	-	-
Foreign equities and equity funds	41,60	-	10,07	61,85	41,60	41,60	-	-	-	-	-	-
Local bonds and debts	3,73	-	-	-	3,73	3,73	-	89,01	87,90	99,29	100,25	101,04
Foreign bonds and debts	31,55	-	73,23	18,51	31,55	31,55	30,63	-	-	-	-	-
Cash and Cash equivalents	16,63	100,00	14,39	15,50	16,63	16,63	69,37	10,99	12,10	0,71	-0,25	-1,04
Loans	0,05	-	-	-	0,05	0,05	-	-	-	-	-	-
Property Investments	6,16	-	2,31	4,14	6,16	6,16	-	-	-	-	-	-
	100,00	**100,00**	**100,00**	**100,00**	**100,00**	**100,00**	**100,00**	**100,00**	**100,00**	**100,00**	**100,00**	**100,00**
Annualised return (net of fees) for 2025	3,44	0,00	2,50	3,95	3,70	2,91	1,51	-0,09	0,09	-0,77	0,89	N/A

Asset class – Ex Ethniki funds	Ex Ethniki Active Cash	Ex Ethniki Fund	Ex Ethniki Guaranteed Fund	Ex Ethniki New Guaranteed Return Fund	Ex Ethniki Conservative Fund	Ex Ethniki Balanced Fund	Ex Ethniki Aggressive Fund
31.12.2025	%	%	%	%	%	%	%
Local equities and equity funds	-	0,87	0,04	-	-	0,03	2,11
Foreign equities and equity funds	-	25,37	-	-	20,82	13,59	48,39
Local bonds and debts	-	14,76	15,24	4,41	6,44	10,95	3,50
Foreign bonds and debts	-	16,25	63,82	60,61	33,39	34,00	11,95
Cash and Cash equivalents	100,00	31,16	20,90	34,98	39,35	41,43	34,05
Property Investments	-	11,59	-	-	-	-	-
	100,00	**100,00**	**100,00**	**100,00**	**100,00**	**100,00**	**100,00**
Annualised return (net of fees) for 2025	0,77	7,89	0,28	-3,16	2,29	1,83	2,33

Asset class – Eurolife funds	Balanced Fund	Guaranteed Fund	Income Fund	Growth Fund	Manulife Investment Fund	GIC Investors Fund	Conservative Fund	Level Up CY30 Fund	Level Up CY30/2 Fund	Level Up CY33 Fund	Level Up CY33/2 Fund
31.12.2024	%	%	%	%	%	%	%	%	%	%	%
Local equities and equity funds	0,35	-	-	0,31	0,35	0,35	-	-	-	-	-
Foreign equities and equity funds	44,19	-	13,76	62,60	44,19	44,19	-	-	-	-	-
Local bonds and debts	3,26	-	7,67	1,12	3,26	3,26	-	84,51	85,52	99,97	100,00
Foreign bonds and debts	29,15	-	61,39	13,75	29,15	29,15	19,68	-	-	-	-
Cash and Cash equivalents	15,90	100,00	14,46	17,27	15,90	15,90	80,32	15,49	14,48	0,03	-
Loans	0,07	-	-	-	0,07	0,07	-	-	-	-	-
Property Investments	7,08	-	2,72	4,95	7,08	7,08	-	-	-	-	-
	100,00	**100,00**	**100,00**	**100,00**	**100,00**	**100,00**	**100,00**	**100,00**	**100,00**	**100,00**	**100,00**
Annualised return (net of fees) for 2024	9,92	0,00	4,36	13,47	10,20	9,38	2,59	0,09	1,05	N/A	N/A

Other than unit-linked assets:

The composition of other than unit-linked assets and information on income and expenses arising from investments by asset class are shown below:

Asset class	Position as at 31.12.2025	Income/gains and losses – 2025	Position as at 31.12.2025 – Ex ethniki	Position as at 31.12.2024	Income/gains and losses - 2024
	%	€'000	%	%	€'000
Government Bonds	9,17	318	55,06	7,76	177
Corporate Bonds	2,19	207	-	3,66	134
Cash and deposits	2,78	19	11,82	8,73	291
Mortgages and loans	0,28	-	-	0,26	-
Properties	19,31	528	14,88	20,85	678
Collective investments undertakings	66,27	839	18,24	58,74	1.408
	100,00	**1.911**	**100,00**	**100,00**	**2.688**

All assets are classified at fair value through profit and loss except other than unit-linked government and corporate bonds that are classified at fair value through other comprehensive income. All ex-Ethniki assets acquired are classified at fair value through profit and loss (unit-linked and other than unit-linked).

A.4 Other

There have been no other significant activities undertaken by the Company other than its insurance activities. No other material matters arose in respect of the business or performance of the Company.

B. System of Governance

B. System of Governance

The Company has in place a system of governance which aims to provide the sound and prudent management of the business. The Company's governance system includes a transparent organisational structure with a clear allocation of responsibilities and appropriate segregation of duties.

B.1 General information on the System of Governance

B.1.1 Roles & Responsibilities of the Board, Senior Management and Key Functions

Board of Directors

The Board of Directors (BoD/Board) maintains overall responsibility for the management of the Company, including ultimate oversight of the Company's operations. As at the end of 2025, the Board consisted of 7 members, of which 4 were Independent Non-Executive Directors, and 3 were Executive Directors.

In addition, an Independent Non-Executive Director resigned on 06/01/2026 for personal reasons. The Company has initiated the relevant replacement procedures, in accordance with applicable governance and regulatory requirements.

The Board of Directors monitors the performance of Senior Management and gives guidance and advice, where appropriate. In fulfilling its oversight responsibilities, the Board regularly reviews and discusses reports submitted by Senior Management and internal control functions regularly and it maintains active and open communication with the General Manager and Senior Management.

In general, the responsibilities of the Board include the following:

- Setting the strategy, tone, culture and values of the Company;
- Establishing the Company's internal control and risk management systems and monitoring their implementation and effectiveness;
- Overseeing Senior Management and establishing sound business practices and strategic planning;
- Setting the Company's risk appetite and risk tolerance limits at a level which is proportionate with the strategic goals of the Company and the nature, scope and complexity of its activities;
- Defining and approving the Company's policies and procedures to ensure its sound operation and compliance with regulatory requirements, taking appropriate measures to address any deficiencies.

Overview of Board and Committees



Board Committees

The Board has established two Committees, the Risk Committee and the Audit Committee, to assist it in discharging its obligations. Matters not reserved to the Board are delegated to the aforesaid Board Committees. However, such delegation does not relieve the Board of its collective responsibility for the discharge of its duties. The terms of reference of the two Committees set out the composition, meeting requirements, responsibilities and authority delegated from the Board to each Committee as well as the reporting requirements of the Committees to the Board.

Risk Committee

The Chairperson of the Risk Committee is an Independent Non-Executive Director who reports to the Board the activities of the Risk Committee. The Risk Committee is composed exclusively of 3 Independent Non-Executive Directors.

The main purpose of the Committee is to review on behalf of the Board, the aggregate risk profile of the Company, including performance against Risk Appetite for all risk types and ensure that both Risk Profile and Risk Appetite remain appropriate. The responsibilities of the Committee include:

- Reviewing management proposals on the desired risk strategy of the Company and assisting the Board in overseeing the effective implementation of risk strategy by management;
- The oversight of the development, implementation and maintenance of the Company's overall Risk Management Strategy and Framework;
- Review and approval of all Risk Management policies of the Company;
- Determining the adequacy and effectiveness of the Company's Risk Management System and Risk Management Function;
- Monitoring and reviewing reports to external stakeholders on risk matters.

Audit Committee

The Chairperson of the Audit Committee is an Independent Non-Executive Director who reports to the Board the activities of the Audit Committee. The Audit Committee is composed exclusively of 3 Independent Non-Executive Directors.

The Audit Committee is responsible for the review and monitoring of, among other things:

- The effectiveness of the Company's system of internal controls;
- The integrity of the Company's financial statements;
- The effectiveness of the internal and external audit processes;
- The Company's relationship with its external auditors;
- The adequacy and effectiveness of the Company's Internal Audit Function and Compliance Function;
- The adequacy of the communication between the Board, Management and the Control Functions.

It is also responsible for the review and approval of all Compliance policies of the Company.

Management Committees

Executive Committee (ExCo)

The Company has established an Executive Committee (ExCo) consisting of individuals from Senior Management. The ExCo is entrusted with the implementation of the business plan and the risk management strategy as determined by the Board of Directors. As of 31 December 2025, the ExCo was composed of 7 individuals in managerial roles, including the General Manager, who also serves as the Chair of the Committee.

The General Manager has overall responsibility and oversight for all the business operations of the Company and is supported by the Managers of each of the Company's Divisions. Each Division is assigned a defined mandate and set of responsibilities, which are clearly communicated to staff members and are subject to adjustment in response to evolving business needs and developments.

The Executive Committee (ExCo) is responsible for ensuring the effective governance and management of the Company, whilst promotes and maintains a culture of heightened awareness and responsibility among the Management Team and all staff members. The ExCo's core responsibilities include:

- Overseeing the Company's operations and providing day-to-day managerial direction;
- Implementing the Company's strategy by setting objectives for all business areas, functions, and supervisors. This includes: (i) the implementation of the risk management policy (ii) setting specific risk management limits and controls and assessing their performance (iii) the continuous monitoring of risk Management against the approved risk appetite of the Company;
- Overseeing the implementation of polices and recommending changes to internal policies and procedures;
- Coordinating and managing Company activities, assigning duties to personnel, and promoting accountability and reporting;
- Developing, reviewing, and improving mechanisms and processes to ensure an effective internal control system.

Asset Liability Management (ALM) Committee

The ALM Committee consists of 5 members which include the General Manager, Chief Actuary, Risk Manager, Investment Manager, and Chief Financial Officer. It is chaired by General Manager.

The responsibilities of the ALM Committee include, among others:

- Overseeing the prudent management of Eurolife's own asset portfolio and ensuring that assets and liabilities are in accordance with the ALM targets and tolerance levels set out in the Company's ALM policy;
- Achieving the best possible return within its risk appetite limits;
- Recommending risk strategy/risk appetite for financial risks to the Risk Committee;
- Monitoring regulatory changes (capital, liquidity and other) and the consequences of those changes on the Company;
- Reviewing and adopting a capital management plan in accordance with the Company's Capital Management Policy, considering the size and nature of the risks undertaken, in order to ensure that the Company has adequate capital and liquidity.

Investment Committee

The Investment Committee consists of 5 members, including the General Manager, Chief Actuary, Risk Manager, Investment Manager, and Chief Financial Officer. It is chaired by General Manager. The purpose of the Committee is to oversee the management of Eurolife's unit-linked funds and to ensure that they are prudently managed having regard to their published objectives and having in mind solely the interests of the policyholders, always adhering to the Prudent Person Principle.

The responsibilities of the Investment Committee include, among others:

- Setting, reviewing and monitoring compliance with investment policies, investment strategies and guidelines, investments processes and procedures;
- Setting and reviewing of asset allocation of Eurolife's unit-linked funds based on market expectations;

- Ensuring proper risk management practices are applied and monitoring performance of external investment managers as against the Company Investment Policy.

Other management committees are also established to support the effective oversight and management of specific functional areas and responsibilities.

Key Control Functions

To strengthen its internal control system, the Company has set up the following internal control functions, in accordance with Solvency II requirements:

- Risk Management Function
- Actuarial Function
- Compliance Function
- Information Security Function
- Internal Audit Function

Risk Management Function

The purpose of the Risk Management Function (RMF) is to facilitate the effective implementation of the risk management system of the Company and to design the risk management processes and reporting procedures required to identify, assess, monitor and report every type of risk inherent in the Company's operations. It is also responsible for monitoring the risk appetite and tolerance limits set by the Board and for preparing and submitting to the Board the "Own Risk and Solvency Assessment" (ORSA) Report.

To facilitate the most effective operation and the objectivity of the risk management system, the RMF is operationally independent from risk-taking functions (e.g. underwriting and claims) and reports directly to the Risk Committee to act independently from Senior Management.

The Risk Management Function is subject to the audit of the Internal Audit Function.

Actuarial Function

The Actuarial Function is responsible for the calculation of the technical provisions, including the assessment of the data quality and the comparison of best estimates against experience. It provides its opinion in relation to the overall underwriting policy and the reinsurance arrangements of the Company and contributes to the effective implementation of the risk management system in respect of the ORSA and Minimum Capital Requirement (MCR)/Solvency Capital Requirement (SCR) calculations. The Actuarial Function reports directly to the Risk Committee and hence has direct access to the Board, to ensure its operational independence and safeguard its ability to escalate important issues.

The Actuarial Function is subject to the audit of the Internal Audit Function.

Compliance Function

The Compliance Function is responsible for ensuring that all actions undertaken by the Company are at all times in compliance with the applicable laws and regulations. It is also responsible to identify, assess and manage the compliance risk that the Company might face and to assess the appropriateness of the procedures and policies in place. In addition, it may suggest organisational and procedural changes to ensure that identified reputational and compliance risks are appropriately managed. The Compliance Function is independent of operational activities. It has direct access to the Audit Committee and the Board, to escalate issues and act independently from Senior Management.

The Compliance Function is subject to the audit of the Internal Audit Function.

Information Security Function

The Information Security Function is responsible for ensuring the confidentiality, integrity and availability of company information and safeguarding information and communication technology (ICT) systems through established and approved information security policies, processes and controls based on regulatory guidelines and requirements, international standards and best practices. It is also responsible for the identification, periodical assessment and monitoring of information security risks as well as providing expert opinion and guidance where needed to manage them effectively and, where applicable, proactively in a secure manner.

It reports directly to the Risk Committee and administratively to the Director Insurance Services. For oversight purposes, it reports to the BOC Group Information Security Division.

The Information Security Function is subject to the audit of the Internal Audit Function.

Internal Audit Function

The Internal Audit Function (IAF") is responsible to assess the design adequacy and operating effectiveness of the Company's internal control framework, corporate governance and risk management processes. The IAF undertakes scheduled audit engagements and monitors the implementation progress of recommendations arising from internal and external reviews, the results of which are directly reported to the BoD, through the Audit Committee. An Annual Audit Report is submitted to the Company's Board of Directors, through the Audit Committee providing the internal audit opinion based on the work carried out in relation to the Company's operations during the year.

B.1.2 Material changes in the system of governance during 2025

During the year 2025 the following changes in the Company's governance system took place:

- The Executive Chairman of the Board served until 18/11/2025. On the same date, a newly appointed Independent NED was appointed and assumed the position of Chairman.
- The Company appointed three new Independent NEDs on 18/11/2025.
- The two previous Independent NEDs resigned on 18/11/2025.
- One Executive Member resigned on 18/06/2025.
- Two non-independent, non-executive Members resigned on 18/11/2025.
- Effective July 2025 and following the formal approval of the Audit Committee and the Board of Directors, the Legal & Compliance Function was restructured into two separate units to enhance governance and strengthen compliance oversight.
- The Company changed its organisational structure in December 2025, effective from 1 January 2026 with no impact on the reporting lines or the independence of its control functions; the only change related to the separation of the Actuarial Function and the Risk Management Function into two distinct units.

No other changes have taken place within 2025.

B.1.3 Remuneration Policy and Practices

Principles of remuneration policy

The main principles of the applicable remuneration policy are as follows:

- The Company's remuneration policy aims to align the remuneration of directors, executive management and staff with the business strategy, objective and long-term interests of the Company,
- The remuneration promotes and is consistent with sound and effective risk management and does not encourage excessive risk taking that exceeds the level of tolerated risk of the Company,

- Fixed remuneration is the main form of remuneration of staff and Executive Management and comprises salary and any applicable allowances as determined by employment contracts and collective agreements the Company is subject to,
- No Director is involved in deciding his/her remuneration,
- The remuneration of non-executive directors is not linked to the profitability of the Company but is fixed and considers the responsibilities and time devoted by the Directors for the execution of their duties.

Variable Remuneration

In the year 2025, the Company established a Short-Term Incentive Plan. This involves variable remuneration in the form of cash to selected employees, and will be driven by both delivery of the Company's Strategy, as well as individual performance.

Supplementary pension or early retirement schemes

Board Members that are not Executive Management are not entitled to supplementary pensions or early retirement schemes. The Company has a hybrid provident fund scheme for all its employees which is based on both defined benefit and defined contribution. All employees are obliged to contribute to the provident fund a set percentage of their monthly salary and the Company is also obligated to contribute a percentage based on the employee's salary which is set by the collective agreement the Company is subject to.

B.1.4 Material Transactions during 2025

The Company has a tied-agent agreement with Bank of Cyprus for promoting its products. A commission is payable for this service. In addition to the above, the Company received rental and interest income under its normal course of business from Bank of Cyprus. Payment of two interim dividends was also made during the year 2025 to Bank of Cyprus. In addition to the above, BOC provides general support services to the Company.

Transactions with members of the BoD and Executive Management include Directors' fees, salary compensations and retirement benefit plan contributions, as well as the collection of insurance premiums and payment of claims in the normal course of business.

No other material transactions were undertaken during the year 2025 as between the Company, its shareholders, or members of the administrative, management or supervisory body and other key function holders.

B.2 Fit and Proper Requirements

B.2.1 Requirements for skills, knowledge and expertise

The Company ensures that all persons who effectively run the Company or hold the Key Functions (the "Assessed Persons") fulfill the following requirements:

- They have the requisite experience, specialization and knowledge for the discharge of their duties and responsibilities (the 'fitness test').
- They act in honesty, reliability and integrity, characteristics which promote the culture of compliance in the Company (the 'propriety test').

A person must satisfy the following criteria to be considered fit and proper to hold an Assessed Person position:

- Competence
- Character
- Diligence
- Honesty

- Integrity
- Judgment to perform his/her duties
- Personal reliability
- Good reputation

B.2.2 Fit and proper assessment process

In line with the Company's Fit and Proper policy, assessments for an Assessed Person position are conducted as follows:

- Before a person is appointed; and
- After their appointment if negative information relating to the assessment becomes known to the Company or where events make it necessary.

Approval by the Regulator is required for the appointment of any Assessed Persons based on fit and proper requirements. The Company's Secretary is responsible for ensuring that such approvals are obtained regarding the members of the Board. For all other Assessed Persons, the Compliance Function is responsible for liaising with the regulator to obtain approvals.

If, following the re-assessment of an Assessed Person, it is concluded that such person no longer complies with Fit and Proper Requirements, the Compliance Function shall notify the regulator, explaining the reasoning for the removal of the person, or in the event that the person remains in that position, the reason such person has remained in the position and the action that is being taken to replace such person.

B.3 Risk Management System and ORSA process

B.3.1 Risk Management System

The purpose of the Company's risk management system is to provide a clearly defined and well documented risk management strategy that sets the Company's risk management objectives and overall risk appetite, taking into consideration the Company's strategic goals. In addition, it aims to set appropriate processes and procedures which enable the Company to identify, assess, manage, monitor and report the risks to which the Company is or might be exposed in the future.

For this purpose, various risk management policies, which facilitate the control and monitoring of the Company's risk exposures, in line with the regulatory requirements, have been documented by the Risk Management Function, reviewed by the Risk Committee and approved by the Board of Directors, which bears the ultimate responsibility for their application and embedment within the Company's system of governance.

The risk management system sets the principles for risk governance that ensures the establishment of clear responsibility boundaries and the proper segregation of duties in relation to risk management. It is based on the "three lines of defence" model, which ensures that the risk management is a core element of the overall responsibilities of the whole Company, including the Board, its Committees, the Senior Management and the Business Units, and it is integrated in the Company's decision-making process.

In particular, the "first line of defence" with regards to risks is fundamentally the Business Units i.e. those units with responsibility to decide and execute decisions and to manage the risks arising on a day-to-day basis. The core responsibilities of the "first line of defence" are to execute the Company's strategy, meet business performance targets, implement policies and proactively manage risks that arise from the Company's daily operations.

The "second line of defence" is essentially the Risk Management Function, the Compliance Function and the Actuarial Function and its role is to provide risk oversight and an independent and objective challenge to the "first line of defence".

The "third line of defence" is the Internal Audit Function. Its role is to act as an independent control body with the purpose of providing assurance on the effectiveness of the Company's risk management system.

The Company operates a distinct RMF which is operationally independent from the Company's risk-taking functions. The adequacy and effectiveness of the controls and risk mitigating strategies in place, as well as the design and effectiveness of the risk management system, are assessed by the Internal Audit Function which reports its findings to the Audit Committee/Board, making relevant recommendations for improvement.

Among the responsibilities of the Board, and following relevant recommendation by the Risk Committee, is the approval of the Company's Risk Appetite Framework (RAF), which forms part of the decision-making process of the Company. Risk appetite is defined as the degree of risk that the Board is willing to accept in the pursuit of its strategy, considering its financial strength and the nature, scale and complexity of its business activities. The RAF is subject to review on an annual basis.

Impact of the Merger on the Risk Management System

As part of the legal and operational merger concluded on 23 December 2025, the Company incorporated the transferred business into its existing risk management system. The integration process included the following enhancements:

- Underwriting risk integration: Underwriting-related considerations arising from the merged portfolios were monitored through the Company's existing RMF processes, including conduct- and retention-related integration risks identified during the transition period.
- Investment and market risk alignment: Transferred assets were brought under the Company's market-risk, investment-risk and ALM monitoring, with ongoing compliance assessed against the Risk Appetite Framework. ORSA 2025 was updated to reflect integration-related scenarios.
- Operational risk assessment: During the integration phase, operational risks such as system and process alignment and data-access considerations were identified and monitored through dedicated workstreams. Mitigating actions were applied where appropriate, and transitional operational risks were reflected in the ORSA 2025 cycle.

Overall, the integration was carried out through the Company's established governance processes, with main emerging risks were identified and escalated to Management and the Risk Committee.

B.3.2 ORSA process

A key component of the risk management system is the "Own Risk and Solvency Assessment" (ORSA) process. The ORSA is a forward-looking process, and it is proportionate in its sophistication to the nature, scale and complexity of the Company's business activities. It represents the Company's own view and understanding of its risks, overall solvency needs and adequacy of its own funds.

The ORSA process is designed and implemented in the following steps:

- Definition of the driving factors for the ORSA planning,
- Identification and classification of risks,
- Preparation of capital planning for the next 3 to 5 years,
- Stress testing and capital allocation,
- Documentation of the ORSA outcome,
- ORSA adoption in the decision-making process of the Company.

In particular, the ORSA enables the Company to properly identify and manage the risks it faces or could face in the future and determine the amount of own funds necessary to ensure that its overall solvency needs are always met over its business planning period. In order to determine its overall solvency needs, the Company applies stress testing scenarios to the forward-looking capital plan, and based on its risk profile, it determines if additional capital over and above the SCR is required.

The ORSA process is ultimately owned and approved by the Company's Board of Directors. However, various bodies, functions and business units of the Company have different roles and responsibilities for the implementation of the ORSA process. These are mainly assigned to the RMF, Actuarial Function,

Finance Department, Senior Management and the Risk Committee. The Internal Audit Function conducts, as necessary, as per the risk-based internal audit methodology adopted, an independent review regarding the ORSA process and its outcome to ensure that it is appropriately designed and implemented.

The ORSA is performed on an annual basis, and the timing of its performance coincides with the Company's financial and strategic planning to allow integration with the decision-making process. Should any material changes occur, the ORSA may be performed at a more regular interval or on an ad-hoc basis. Such changes include significant changes in the Company's risk profile, business plan and the economic environment in which the Company operates.

The outcome of the ORSA process is documented in the ORSA Report, which is prepared by the RMF and submitted to the Risk Committee to review it and challenge it before recommending it to the Board for approval. The ORSA outcome is used by the Board to decide on the actions that can be taken in unforeseen circumstances in the future. Such actions include measures to improve the Company's internal control system, risk management system and its overall governance framework. Following the Board approval, the ORSA Report is submitted to the Regulator, in accordance with the regulatory requirements.

The ORSA 2025 report was based on the merged entity.

B.4 Internal Control System

B.4.1 Description of the Internal Control System

The Company's Internal Control System (ICS) is designed to provide reasonable assurance on the following:

- Effectiveness and efficiency of operations
- Reliability of financial and non-financial information
- Adequate control of risks
- A prudent approach to business
- Compliance with laws and regulations, and internal policies and procedures

Effective internal controls help the Company protect and enhance shareholders' value and reduce the possibility of unexpected losses or damage to its reputation. The Board is ultimately responsible for overseeing and maintaining the adequacy and effectiveness of the internal control and risk management systems.

The Internal Control System of the Company is comprised of the following principles:

- Control Environment and Culture: The Board is responsible for promoting a high level of integrity and for establishing a culture within the Company that emphasizes and demonstrates to all levels of personnel the importance of Internal Control. Senior Management is responsible for the implementation of the Internal Control culture and principles. All staff members need to understand their role in the ICS and be fully engaged in the process.
- Risk Assessment: The Company must regularly assess both the internal and external risks that it faces. Assessment should include the identification and analysis of all the significant risks that an insurance company is exposed to.
- Control Activities and Segregation of Duties: An adequate Internal Control System requires the implementation of effective and efficient control activities at all levels of the entity which should be implemented in line with the goals and strategies set out by the Board and should involve all staff. As an integrated part of daily business, these activities should be reviewed and recorded on an on-going basis. An appropriate segregation of duties and responsibilities is also required, both at individual level and between Key Functions.
- Information and Communication: The Company should have reliable information at all levels within the organization, in order to define, achieve and review the objectives set out by the Board.

The effectiveness of communication procedures should be ensured, whether such communication is internal, external or includes formal or informal paths.

- Information and Communication Security: Security controls for the risks inherent in Information and Communication dissemination and technology must be established, allowing for the effective management of such risks.
- Monitoring: Appropriate monitoring systems must be applied on an ongoing basis, complemented with separate evaluations.

B.4.2 Implementation of the Compliance Function

Compliance Function is an integral part of the ICS of the Company. The role of the Compliance Function throughout the Company is to proactively facilitate the management of compliance risk by identifying, assessing, monitoring and reporting the compliance risk exposure of the Company. This serves to assist the Company to carry on its business successfully and in conformity with regulatory and ethical standards.

In particular, the Compliance Function establishes, implements and maintains appropriate mechanisms and activities to:

- Promote and facilitate a corporate culture of integrity and ethical values within the Company
- Monitor the adherence of the Company to all applicable compliance policies and procedures
- Identify and assess on an on-going basis significant change in the legal and regulatory environment in which the Company operates and identify the compliance risk that could arise from such changes
- Formulate proposals for organisational and procedural changes to ensure that identified reputational and compliance risks are appropriately managed
- Prepare and subsequently review and revise accordingly Company policies on key compliance-related issues
- Assess the appropriateness of the Company's compliance procedures and guidelines, follow up identified deficiencies promptly and put forth suggestions for improvements as necessary
- Oversee the complaints process and utilizing customer complaints as a source of relevant information in the context of its general monitoring responsibilities
- Organize regular training and educational programs for Management and staff on compliance and regulatory matters

The responsibilities of the Compliance Function are carried out under an annual compliance program/action plan that sets out its planned activities, such as the implementation and review of specific policies and procedures, compliance risk assessment, setting corrective actions to address any control weaknesses that are identified and educating staff on compliance matters.

In addition, the Compliance Function maintains a fully updated compliance chart/register of the existing regulatory framework (laws, regulations and self-regulatory standards) and identifies in cooperation with the relevant departments the compliance obligations emanating from each regulatory framework.

On a quarterly basis, the Compliance Function provides a written report to the Senior Management and Audit Committee detailing the effectiveness of implementation of the compliance chart, the progress on the compliance action plan, the compliance risk assessment results during the reporting period, as well as any identified breaches and/or deficiencies and the corrective measures recommended.

B.5 Internal Audit Function

B.5.1 Implementation of the Internal Audit Function

The Internal Audit Function ("IAF") is an independent function responsible for providing its opinion to the Company's BoD, through the Audit Committee, through assessing the design adequacy and operating effectiveness of the Company's internal control framework, corporate governance and risk management processes. The IAF undertakes scheduled audit engagements and monitors the implementation progress of recommendations arising from internal and external reviews, the results of which are directly reported to the Company's BoD, through the Audit Committee. An Annual Audit Report is submitted to the Company's BoD, through the Audit Committee providing the internal audit opinion based on the work carried out in relation to the operations of the Company during the year.

The Company outsources the IAF to BOC Group's Internal Audit Division (IA). Notwithstanding any outsourcing, the Company remains fully responsible for discharging all its obligations regarding the IAF. Risks inherent in the outsourcing of the IAF are identified, monitored and appropriately mitigated and the service provider is properly supervised and managed.

B.5.2 Independence of the Internal Audit Function

IA reports directly to the Company's BoD, through the AC, as well as to the BOC Group's Audit Committee. The BOC Group's Audit Committee is responsible for monitoring the independence, adequacy, and effectiveness of the IA. The BOC Internal Audit Director (IAD) confirms on an annual basis the BOC Group's BoD, through the BOC Group Audit Committee, the organisational independence, adequacy and effectiveness of the internal audit activity. This is in line with Principle 7 of the Global Internal Audit Standards, which states that the IAD must confirm to the Board the organisational independence of the IA at least annually. Independence is defined as freedom from conditions that impair the IA's ability to carry out its responsibilities in an unbiased manner. IA informs the Company's BoD, through the Audit Committee, on the independence, adequacy and effectiveness of the internal audit activity through the Annual Audit Report submitted to the Company's Audit Committee.

B.6 Actuarial Function

The primary role of the Actuarial Function is to ensure that technical provisions are established with respect to all insurance obligations towards policyholders and beneficiaries of insurance contracts. In particular, the Actuarial Function ensures that the methodologies and assumptions used in the calculation of the technical provisions are appropriate for the specific lines of business of the Company and for the way the business is managed. It assesses the uncertainty associated with the estimates made in the calculation of technical provisions and it examines the sufficiency and quality of relevant data to be considered in the reserving process.

When comparing best estimates against experience, it reviews the quality of past best estimates and uses the insights gained from this assessment to improve the quality of current calculations. The comparison of best estimates against experience includes comparisons between observed values and the estimates underlying the calculation of the best estimate, to draw conclusions on the appropriateness, accuracy and completeness of the data and assumptions used as well as on the methodologies applied in their calculation.

It also contributes to the effective implementation of the risk management system and calculates the MCR/SCR based on regulatory requirements and cooperates closely with the Risk Management Function for the performance of the stress tests as part of the ORSA process.

In addition, the Actuarial Function advises Senior Management and the Board of Directors on the overall underwriting policy and the reinsurance arrangements of the Company. Specifically, the Annual Actuarial Report submitted to Senior Management and the Board of Directors includes, among other things, an opinion on the underwriting and adequacy of reinsurance arrangements and the activities carried out by the Actuarial Function together with relevant recommendations for improvement.

B.7 Information Security Function

The primary role of the information security function is to ensure the confidentiality, integrity and availability of the company's information and its related information and communication systems (ICT). This is achieved through the enforcement of information security policies, procedures and controls, based on regulatory guidelines and requirements, international standards and best practices. These policies, procedures and controls are periodically reviewed for their effectiveness and improvement through established programmes that include information security risk assessments, internal and external penetration testing, threat intelligence, awareness training of personnel, associates and other relevant stakeholders, involvement in operational resilience testing and continuous monitoring of networks and systems. In addition, it collaborates with business units and other control functions to ensure that the company remains compliant with information security regulatory requirements. Finally, it provides advice, expert opinion and guidance where needed for other business units, senior management and executives for proactive management of information security.

B.8 Outsourcing

The Company has established an Outsourcing Policy to ensure compliance with the relevant regulatory requirements and the effective control and management of the risks associated with the outsourced arrangements.

Regarding the outsourcing of any function or insurance activity the following shall apply as a minimum:

- A detailed examination/due diligence shall be undertaken prior to outsourcing the function or insurance activity for the purposes of:
    - allowing the Company to understand the main risks that might arise from the outsourcing,
    - identifying the most suitable strategies for the mitigation/management of such risks,
    - ensuring that the Service Provider has the necessary financial resources, ability, capacity and any authorization required by law to perform the outsourced activities reliably and professionally.
- The Company shall remain fully responsible for the discharging of all its obligations under a function or insurance activity that is outsourced.
- The Company ensures that there is effective supervision of the outsourced function or activity. In addition, it ensures that the Company's regulator will have access to all relevant data held by the Service Provider to which the function or insurance activity is outsourced, regardless of whether such Service Provider is a regulated or unregulated entity.
- The Company ensures that there is a Non-disclosure Agreement in place with the Service Provider if any confidential information is to be provided to the Service Provider.
- The Company safeguards that in any arrangement with a Service Provider it shall have the right to terminate the Outsourced arrangement.

In accordance with the Company's Manual, prior to the outsourcing of an activity or function, an assessment is carried out by the Outsourcing Officer as to whether the outsourced activity or function has the potential to be considered a critical or important service or activity, and the Legal Department provides confirmation as to the result of such an assessment.

As at the end of 2025, the following critical functions or activities are outsourced:

- The Internal Audit control function of the Company;
- The handling and investigation of healthcare claims;
- Portfolio management services related to Class VII products (management of group pension funds);
- Storage of all policy documents; and
- IT services

All the above service providers are in Cyprus.

B.9 Adequacy of the system of governance

The Board of Directors of the Company is committed to good governance which is vital to creating trust and engagement between the Company and its stakeholders and contributes to its long-term success. A key objective of the governance framework of the Company is to ensure compliance with applicable legal and regulatory requirements however, proportionate to the size and complexity of the Company's operations, it also applies best practices of corporate governance and corporate administration.

The Company aims to ensure on an ongoing basis that it is a modern, transparent and competitive organization. By adopting best practices, the Company achieves dynamic and effective communication with the Board, management and shareholder leading to a successful implementation of its strategy and a more than adequate framework of corporate governance.

C. Risk Profile

C. Risk Profile

Solvency II is a risk-based solvency requirement framework which requires the Company to hold capital against underwriting, market, credit and operational risks. The Company aims to maintain sufficient available capital to cover all risks it faces and to always satisfy the regulatory requirements.

The Solvency Capital Requirement (SCR) is the economic capital that should be held to ensure that the Company can meet its obligations to policyholders and beneficiaries with certain probability and should be set to a confidence level of 99,5% over a 12-month period. That requirement limits the chance of financial loss for the following year to a 1-in-200-year event. There is also a Minimum Capital Requirement, which represents an 85% confidence level and should not be less than 25% of the SCR. The Company uses the standard formula to calculate the SCR, as provided by the European Insurance and Occupational Pensions Authority (EIOPA).

The Company's solvency position as at 31 December 2025 is equal to 226% which is well above the minimum regulatory requirement. Further relevant quantitative information in relation to the Company's capital requirements and solvency position can be found in Section E, "Capital Management" of this Report.

A key component of the risk management system and the ORSA process is the annual risk identification and assessment exercise, through which the Company assesses its position regarding the different risks to which it is or might be exposed. The assessment covers all risk types, including less-quantifiable risks, and aims to determine the Company's risk profile taking into consideration its risk appetite. It is based on quantitative and qualitative criteria, prior experience and expert judgment.

As part of the ORSA process, the Company performs stress tests on material risks using some common and some extreme but plausible scenarios to examine the impact on its future capital and solvency position. The purpose of this exercise is to identify whether the Company will remain solvent and adequately capitalised should any of these tests or scenarios materialise. The results of the stress tests performed in 2025 are presented under each relevant risk category in the following Chapters.

The Company has also performed various sensitivity analyses to illustrate how the Company's solvency position would change, if a single factor is adjusted, but all other circumstances remain unchanged. Across all sensitivity analyses performed in 2025, the solvency ratio remained well above the minimum regulatory requirement. A reverse stress test is also performed to identify potential business vulnerabilities. This exercise starts from an outcome of business failure and identifies circumstances where this might occur. Based on the results of the exercise carried out in 2025, it was concluded that various extreme events would have to occur simultaneously for the solvency ratio to drastically fall below a level that the Company would face a business failure.

Impact of the merger on the Company's risk profile

Following the integration of the transferred business, the Company's risk profile evolved in several areas, reflecting the characteristics of the merged operations. The integration introduced additional considerations across insurance, market, credit and operational risks all of which were monitored through the RMF and reported to the Executive Committee and the Risk Committee.

- Insurance Risk: The merger introduced exposure to additional products and distribution channels. Integration-related risks were identified and monitored through dedicated workstreams.
- Market Risk: transferred assets were incorporated into the Company's existing market-risk and ALM monitoring framework. The Company continued to monitor the exposures, remaining within the Risk Appetite limits. ORSA 2025 also considered the potential market-risk impact of the merged portfolios.

- Credit Risk: counterparty and reinsurance exposures continued to be monitored in line with existing credit-quality requirements, with no integration-related credit risk concerns identified during 2025.
- Operational risk: Operational risks such as system and process alignment were monitored through dedicated workstreams, with mitigating actions implemented where needed. ORSA 2025 included scenarios reflecting integration-related operational impacts.

Overall, the Company remained within its declared Risk Appetite across all major risk categories during the integration period, and the impact of the merged business was managed through the established governance, monitoring and reporting processes.

C.1 Underwriting Risk

Underwriting risk is defined as the risk of loss or of adverse change in the value of insurance liabilities, due to inadequate pricing and provisioning assumptions. The Company is exposed to life and health underwriting risks, which are further broken down to sub-categories of risks, as described below.

Life Underwriting Risk

Out of the particular constituents of Life Underwriting Risk, those that affect the Company's business are the mortality risk, the expense risk, the lapse risk, the catastrophe risk and the longevity risk.

Mortality Risk

It is the risk of loss, or of adverse change in the value of insurance liabilities, resulting from changes in the level, trend, or volatility of mortality rates, where an increase in the mortality rate leads to an increase in the value of insurance liabilities.

As a life insurance company, Eurolife is exposed to the risk of mortality experience being higher than expected, which in turn leads to more claims from insurance policies that provide death cover. This has as a result the amount of claim payments to be higher than expected. Higher mortality experience than expected can arise from misjudgement during assumption setting, inadequate assessment of the risks entailed during underwriting, concentration of risks, etc.

Expense Risk

It arises from the variation in expenses incurred in servicing insurance contracts. Eurolife is exposed to the risk that its expenses are higher than expected. Expense risk can arise from higher-than-expected inflation, lower volume of business than expected, changes in the mix of business, etc.

Lapse Risk

It is the risk of loss or adverse change in liabilities due to a change in the expected exercise rates of policyholder options. The relevant options are all legal or contractual policy holder rights to fully or partially terminate, surrender, decrease, restrict or suspend insurance cover or permit the policy to lapse.

Eurolife is exposed to the risk of lapse rates being higher or lower than expected. The risk of higher-than-expected lapses can incur at the early stage of a policy life cycle, when a policy may lapse before expenses are recovered. The risk of lower-than-expected lapses can incur at the late stage of policies life-cycle, when more policies are in-force creating higher claim costs than expected.

Eurolife is also exposed to mass lapses driven by market conditions and any other one-off shock lapse event.

Catastrophe Risk

This risk stems from extreme or irregular events whose effects are not sufficiently captured in the other life underwriting risk sub-modules. Eurolife is exposed to life-catastrophe risk due to the potential increase in mortality caused by a catastrophic, extreme death event (e.g. pandemic event, plane crash, nuclear explosion, etc.)

Longevity Risk

This is the risk that policyholders live longer than expected. This risk is particularly important for life insurance products such as immediate and deferred annuities as well as certain health contracts and with-profits funds. Eurolife is exposed to this risk through the Endowment with profit contracts offered included in the ex-Ethniki life portfolio.

Health Underwriting Risk

Health underwriting risk module captures the risk of health insurance obligations, and it covers the following sub-risks:

- The SLT Health underwriting risk sub module,
- The non-SLT Health underwriting risk sub module, and
- The health catastrophe risk.

The Company classifies its health-related business (stand-alone and supplementary benefits) into the two categories, SLT Health and Non-SLT Health and determines the capital requirement under each of the relevant risk sub-categories.

The exposure to SLT Health underwriting risk exists due to Eurolife's health insurance obligations pursued on a similar technical basis to that of life insurance, segmented and valued according to the segmentation for life insurance obligations (e.g. accidental death, disability benefits, income protection benefits).

The exposure to non-SLT Health underwriting risk exists due to Eurolife's health insurance obligations not pursued on a similar technical basis to that of life insurance (e.g. medical expenses benefits).

Eurolife is exposed to health-catastrophe risk due to the potential mass accident and pandemic events that may occur and could affect its clients.

Use of Reinsurance as a Risk Mitigation Technique

The Company’s reinsurance arrangements serve to limit its overall underwriting risk exposure as well as to reduce the volatility of its claims and enhance underwriting performance.

The reinsurance arrangements currently in place cover all types of underwriting risks (mortality, morbidity/disability, medical expenses) and potential events relating to significant known aggregations of risk such as realistic disaster scenarios (catastrophe reinsurance arrangement).

Underwriting Risk Management Policy

The Company’s Underwriting Risk Management Policy sets out the policies and procedures for the management of underwriting risk. In addition, a Reserving Risk Management Policy and a Reinsurance Policy are in place.

The Company has in place the following controls for monitoring underwriting risk:

- Use of reinsurance to reduce exposure to mortality, morbidity and medical expense risks,
- The underwriting Department ensures that only insurable risks are accepted and that premiums reflect the unique circumstances of each risk,
- Lapse monitoring is conducted on an annual basis,
- Experience investigations covering mortality, morbidity and expenses are conducted on an annual basis, unless circumstances require a more frequent analysis,
- Product design and pricing aim to minimise adverse client selection and the Company has retained the option to review premium rates at regular intervals throughout the life cycle of certain types of policies.

Underwriting Risk Assessment and ORSA outcome

Underwriting risk was taken into consideration as part of the ORSA 2025 stress-testing framework, which included underwriting-relevant shocks such as mass lapse effects in an economic downturn, temporary lapse increases linked to post-acquisition integration, and higher health claims under a pandemic-recovery scenario. While all scenarios indicated that they would impact the Company's solvency position, the Solvency Ratio remained above the minimum regulatory limit, as stated in paragraph C.2 below.

In addition, a sensitivity analysis was carried out assuming a 10% increase in the best estimate expense assumption together with a 1% increase in the expense inflation rate. Even though this adverse movement in expense assumptions would negatively affect the Company's solvency ratio, the solvency ratio remains above the minimum regulatory requirement, confirming resilience to expense-related underwriting risk.

C.2 Market Risk

Market risk is defined as the risk of loss or of adverse change in the financial situation resulting, directly or indirectly, from fluctuations in the level and in the volatility of market prices of assets, liabilities and financial instruments. It is broken down to interest rate, equity, property, currency, spread and concentration risk.

The Company writes predominantly unit-linked business where the market risk is borne by the policyholder. The greater impact of market risk to the Company arises from its own assets.

Interest Rate Risk

This risk exists for all assets and liabilities which are sensitive to changes in the term structure of interest rates or interest rate volatility, whether valued by mark-to-model or mark-to-market techniques. Eurolife's exposure to interest rate risk arises due to its own investments in interest-sensitive assets such as sovereign bonds, corporate bonds, fixed deposits and notice accounts. It also arises from an increase in the technical provisions when interest rates change and there is no perfect asset-liability matching.

Equity Risk

This risk arises from the level or volatility of market prices for equities. Exposure to equity risk refers to all assets and liabilities whose value is sensitive to changes in equity prices and any assets not shocked in other risk modules.

It is Eurolife's policy not to hold any equities or equity type investments in the other than the unit-linked portfolio.

Property Risk

It arises as a result of sensitivity of assets, liabilities and financial investments to the level or volatility of market prices of property. Types of assets falling under this category are land, buildings, immovable property rights as well as the Company's head office building.

It is Eurolife's policy not to hold any own investments in property other than its head office building and its adjacent parking plot.

Currency Risk

This risk arises from changes in the level of volatility of currency exchange rates. All investments with exposure to non-euro currencies are stressed under this risk. These include all non-euro denominated investments or Funds or Funds of Funds whose underlying stocks or bonds are non-euro denominated even if the actual Fund is denominated in euro.

Eurolife's exposure to currency risk is limited as the majority of its assets and liabilities are denominated in euro.

Spread Risk

This risk results from the sensitivity of the value of assets, liabilities and financial instruments to changes in the level or in the volatility of credit spreads over the risk-free interest rate term structure.

The Company applies this risk to all assets stressed under the interest rate risk. In addition, it applies the spread risk shock to its fixed deposits, if any.

Concentration Risk

It is the risk of accumulating investment exposures with the same counterparty. It applies to assets considered under equity, property and spread risk modules, but excludes assets covered under the counterparty default risk. It also excludes assets backing unit liabilities of unit-linked policies where the investment risk is borne by the policyholder.

Market Risk Management Policy and Prudent Person Principle

The policies and procedures for the management of market risk are documented in the Company's Market/Investment Risk Management Policy and in the ALM Policy. The main objective is to ensure that all investment activities are consistent with the Company's RAF and with the Prudent Person Principle.

In order for the Company to safeguard that investment decisions are taken based on the provisions of the Prudent Person Principle it has established two Executive Committees, the Investment Committee and the ALM Committee, which are responsible for the management of unit-linked assets and own assets, respectively. Committee meetings are held on a quarterly basis, as a minimum, decisions are taken by the majority of votes and relevant information is submitted to the Risk Committee/Board for noting.

Relevant limits have been set within the Company's RAF which are monitored by the RMF and reported to the abovementioned Executive Committees as well as to the Senior Management and Risk Committee. These include, among else, restrictions on own assets (i.e. other than unit-linked assets) in relation to duration, asset classes, counterparty, country, concentration and currency risk exposures.

As regards unit-linked assets (i.e. the assets held in respect of life insurance contracts where the investment risk is borne by the policyholders) the investment objective varies according to the investment strategy of each of the Company's Internal Funds but its broad aim is to achieve the maximum risk-adjusted return for the benefit of the policyholders. Relevant limits have been set according to the mandate of each of the Company's Internal Funds which set specific asset allocation constraints and are continuously monitored. Also, the Company acts in compliance with the Orders issued by the Regulator restricting the types of assets to which policy benefits may be linked.

The Company collaborates with multiple reputable external fund managers with different investment philosophies to allow diversification of fund management. The Company follows a selection process, with specific evaluation and selection criteria, when choosing Fund Managers. The performance and investment process of the chosen Fund Manager is closely and regularly monitored, and the Company ensures that it is able to properly assess and report the assets under management and perform the required solvency capital calculations.

Market Risk Assessment and ORSA outcome

As part of the ORSA 2025 stress-testing framework, market-related shocks, including decreases in bond fund values, changes in interest rates, and ESG-related market movements were assessed. Across all scenarios, the Company's solvency ratio remained well above the regulatory minimum requirement, even though its solvency ratio decreased between 8% to 9% during the projected period. In addition, relevant mitigating actions were approved by the Board during the review and approval of the ORSA Report for 2025.

In addition, sensitivity analyses were performed on interest rates, assuming both a 10% increase and decrease in the interest rate assumption. Both sensitivity analyses resulted to an immaterial impact on the Company's solvency ratio.

C.3 Credit Risk

Credit risk or counterparty default risk is defined as the risk of loss due to unexpected default, or deterioration in the credit standing of the Company's counterparties and debtors.

Eurolife is exposed to counterparty default risk arising mainly from its collaboration with banking and reinsurance counterparties.

Credit Risk Management Policy

The Company has established a Credit Risk Management Policy that sets out the policies and procedures for the management of credit risk. In addition, a Concentration Risk Management Policy is in place.

In particular, the following controls are in place for managing credit risk:

- Counterparty limits are set as part of the Company's risk appetite which is frequently monitored by RMF.
- Credit rating restrictions apply to ensure the high credit quality of both unit-linked assets and other than unit-linked assets.
- Frequent counterparty assessments are performed which consider the counterparty's creditworthiness, financial strength and overall performance and reputation, by using independent and reliable sources.
- Past due items are monitored frequently, at individual and aggregate level, and collections are tracked against previous month.

Credit Risk Assessment and ORSA outcome

During the risk assessment exercise performed in 2025, credit risk was not considered as a material risk for the Company. As part of the ORSA process, a sensitivity analysis was carried out assuming the downgrade of the Company's main reinsurer by two credit quality steps, indicating an immaterial impact on the Company's solvency ratio.

C.4 Liquidity Risk

Liquidity Risk is defined as the risk that the Company is unable to realise investments and other assets in order to settle its financial obligations when they fall due.

Liquidity risk may arise from significant asset-liability mismatches in relation to duration. These may occur due to unexpected outflows and/or inability to liquidate assets or to receive scheduled payments. In this context, liquidity risk arises if there are circumstances where the Company has insufficient liquid or readily realizable assets to meet its commitments.

In addition, the Company is exposed to liquidity risk under a mass surrender scenario. A less likely event giving rise to high one-off payment is the occurrence of a death, accident or disability claim where a very high sum assured is involved or the occurrence of a catastrophic event giving rise to multiple simultaneous claims. However, the latter events will not require the immediate payment of sums as a mass surrender event would.

Other liquidity needs include the payment of commissions to intermediaries and fulfilling regular obligations such as staff salary payments or supplier invoice payments.

Liquidity Risk Management Policy

The Company's Liquidity Risk Management Policy stipulates the policies and procedures for the management of liquidity risk.

The Company has established the following controls for the management of liquidity risk:

- The Company has a very limited appetite for liquidity risk and aims to maintain sufficient assets in liquid form.

- Various daily, weekly and monthly liquidity ratios have been set as part of the Company's risk appetite.
- RMF monitors the level of compliance with liquidity limits on a quarterly basis and reports its findings to the Senior Management and Risk Committee.

It is the Company's policy to hold sufficient liquid assets to meet its financial obligations.

Expected profit included in future premiums

The expected profit included in future premiums is calculated as the difference between the technical provisions without a risk margin and a calculation of the technical provisions without a risk margin under the assumption that the premiums relating to existing insurance and reinsurance contracts that are expected to be received in the future are not received for any reason other than the insured event having occurred, regardless of the legal or contractual rights of the policyholder to discontinue the policy. The amount of expected profit from future premiums as at 31 December 2025 is equal to €46,4m.

Liquidity Risk Assessment and ORSA outcome

As per the risk assessment performed in 2025, the exposure to liquidity risk was not considered material and so no specific stress test was deemed necessary to be performed during the ORSA process, even though it was taken into consideration in the various stress tests carried out.

C.5 Operational Risk

Operational risk is defined as the risk of loss arising from inadequate or failed internal processes, people and systems, or from external events.

The Company has identified, inter alia, the following causes of operational risk:

- Processes: Causes relating to poorly designed processes, deviations from policy, etc.
- People: Causes relating to human errors, fraudulent activity, key person risk, etc.
- Systems: Causes relating to inadequate or obsolete systems, poor system maintenance, etc.
- External Events: Causes mainly having to do with natural disasters or other socio-economic and/or political factors outside the Company's control.

Legal risk exposure is also considered during the operational risk assessment.

Operational Risk Management Policy

The Company has established an Operational Risk Management Policy that sets out the policies and procedures for the management of operational risk.

Operational risk management is the responsibility of all staff across all levels of the Company, as its exposure to operational risk is inherent in all the Company's activities and operations. Through the risk and control self-assessment (RCSA) carried out by the Business Units, with the guidance of the RMF and further oversight from GRMD, operational risk exposures are identified and assessed, and relevant action plans are drawn up to mitigate identified risks. Monthly follow-up is performed for monitoring the progress of agreed mitigating actions.

In addition, the Company has established a process for collecting, evaluating, monitoring and reporting operational risk loss data. The collection of internal loss data is supported by all Business Units of the Company, which have the responsibility to report the operational risk events to the RMF, which in turns ensures that they are properly recorded in the operational loss event database.

Furthermore, the Company's RAF includes a combination of qualitative and quantitative limits and thresholds for all major types of operational risk events.

Operational Risk Assessment and ORSA outcome

During the risk assessment exercise performed in 2025, operational risk was assessed as a material risk for the Company. As part of the ORSA process, stress tests were carried out combining multiple factors, including the materialisation of operational risk events including a cyber-attack event and data-breach scenario with the solvency ratio remaining well above the regulatory limit. In addition, relevant mitigating actions were approved by the Board during the review and approval of the ORSA Report for 2025.

C.6 Other Material Risks

Business risk was assessed as a material risk for the Company during 2025. Business risk refers to the risk that may cause to the Company inadequate profits or even losses and it is influenced by numerous factors, including business plan and strategy, competition and reputation.

The Company closely monitors market conditions to which the business is exposed and is very agile in adjusting its business goals in response to changes in the business, competitive or regulatory environment.

As part of the ORSA process, a stress test regarding business risk was performed in 2025 assuming, among other factors, the consequences caused by the recession of the global and local economy combined with the impact of a cyber-attack event. The results of the combined stress test showed a decrease in the Company's solvency ratio within the range of 1% to 6%, during the projected period. However, the Company was considered adequately capitalised, since its solvency position remained well above the minimum regulatory requirements.

In addition, as part of the ORSA process, a climate change materiality assessment was performed by the RMF, considering the climate change risk drivers (i.e. transition and physical risks). Based on the materiality assessment performed for both sides of the balance-sheet, it was concluded that the most material climate risk driver for the Company is the transition risk on the asset-side, expected in the medium to long-term. Physical risk on the liability side might have an impact in the long-term. The Company will keep monitoring climate change risk developments, taking any actions deemed necessary for mitigating any negative impact on its business and profitability.

C.7 Other information

The Company aims to maintain its risk profile within its risk appetite and in accordance with regulatory requirements. The set risk appetite limits are monitored by the RMF with the use of the Risk Appetite Dashboard, which is reported on a quarterly basis through the Risk Management Report to the Senior Management, Risk Committee and to GRMD, indicating any possible violations and remedial actions taken or planned to be taken. The Risk Committee has the right to escalate to the Board any issues it deems necessary.

D. Valuation for Solvency purposes

D. Valuation for Solvency purposes

D.1 Assets

The primary objective of asset valuation for Solvency purposes is set out in Article 75 of the Solvency II Directive and requires an economic, market-consistent approach to the valuation of assets. According to this approach, assets should be valued at the amount for which they could be exchanged between knowledgeable willing parties in an arm's length transaction. The default reference framework for valuing assets is the IFRS Accounting Standards as adopted by the European Union. The Company's financial statements are prepared in accordance with IFRS Accounting Standards as adopted by the European Union and contain a summary of the significant accounting policies adopted in their preparation.

All assets and liabilities transferred from Ethniki Insurance (Cyprus) Ltd were valued at the transfer date using Solvency II valuation principles, including:

- Recalculation of technical provisions for all acquired life and health portfolios using Solvency II best estimate liabilities and risk margin methodologies.
- Fair value adjustments to transferred assets to align them with Solvency II valuation rules.

The Company's Solvency II balance sheet on 31 December 2025 therefore reflects the merged and fully integrated business.

The following table summarises for each material class of assets, the value of the asset and a description for the bases, methods and main assumptions used for valuation for solvency purposes.

Asset class	Value	Value	Solvency II valuation basis
	31.12.2025 €'000	**31.12.2024 €'000**	
Pension benefit asset	3.350	1.767	Value is based on an external actuarial valuation
Property, plant & equipment held for own use	19.739	16.252	Property: valued based on external valuation report and Ex-Ethniki acquired property valued based on external valuation. Plant & Equipment: valued at cost less accumulated depreciation less any impairment
Investments (other than assets held for index-linked and unit-linked contracts)			
Property (other than for own use)	12.055	12.055	Valued based on external valuation report obtained by independent property valuers.
Bonds	29.148	15.509	Valued at fair value as at the reporting date. The following hierarchy of high-level principles for the valuation of assets is used: • Quoted market prices in active markets (100,0% (2024: 100,0%)).
Collective Investments Undertakings	101.727	79.713	Valued at fair value based on market prices as at the reporting date.
Deposits other than cash equivalents	1.906	613	Valued on the same basis as per IFRS Accounting Standards financial statements.
Assets held for index-linked and unit-linked contracts	915.311	764.595	Includes bonds, equities, collective investments undertakings, properties and

			deposits other than cash equivalents held for index-linked and unit-linked contracts. Valued at fair value as at the reporting date. The following hierarchy of high-level principles for the valuation of assets is used: • Quoted market prices in active markets (97,5% (2024: 97,0%)). • Maximum use of relevant observable inputs and market inputs and as little reliance as possible on undertaking-specific inputs, minimizing the use of unobservable inputs (2,5% (2024: 3,0%)).
Loans and mortgages	414	348	Valued at amortised cost.
Reinsurance recoverables	(18.547)	(6.200)	Reinsurance share Technical Provisions measured in accordance with Solvency II principles
Insurance and intermediaries receivables	5.599	5.445	Includes premiums due and amounts due from agents. Valued on the same basis as per IFRS financial statements.
Reinsurance receivables	8.671	6.730	Includes the current account with the reinsurer and the reinsurance share on incurred outstanding claims. Valued on the same basis as per IFRS Accounting Standards financial statements.
Receivables (trade, not insurance)	1.410	488	Valued on the same basis as per IFRS Accounting Standards financial statements.
Cash and cash equivalents	4.868	11.241	Valued on the same basis as per IFRS Accounting Standards financial statements.
Any other assets	14.936	8.907	Includes tax receivables and related parties balances. Valued on the same basis as per IFRS Accounting Standards financial statements.
Total assets	**1.100.587**	**917.463**	

The differences in valuation between IFRS Accounting Standards valuation assets and Solvency II are summarised below:

	IFRS Financial Statements	Solvency II Framework
Intangible Assets	Measured in accordance with International Accounting Standards (IAS) 38 at cost less accumulated amortization and impaired losses	Measured at zero as they cannot be sold separately and there is no value for the same or similar assets from quoted market prices in active markets
Reinsurance Recoverables	Measured using IFRS Accounting Standards methodology and basis (as per IFRS Accounting Standards financial statements)	Reinsurer's share calculated for Technical Provisions is in accordance with Solvency II principles

D.2 Technical Provisions

Technical Provisions by material line of business:

Technical provisions	Gross Best Estimates (BE)	Risk Margin (RM)	Reinsurance	Net TPs (BE+RM-RI)
31.12.2025	**€'000**	**€'000**	**€'000**	**€'000**
Health Non SLT	1.678	309	(2.236)	4.223
Health SLT	(3.620)	9.979	739	5.620
Life excluding unit linked	(10.595)	15.617	(10.849)	15.871
Unit Linked	822.822	46.559	(6.201)	875.582
Total	**810.285**	**72.464**	**(18.547)**	**901.296**

The figures in the table for 31.12.2025 above belong to the merged entity. In particular €52.080m of net technical provisions correspond to the ex-Ethniki acquired portfolio.

Technical provisions	Gross Best Estimates (BE)	Risk Margin (RM)	Reinsurance	Net TPs (BE+RM-RI)
31.12.2024	**€'000**	**€'000**	**€'000**	**€'000**
Health Non SLT	(200)	288	(2.267)	2.355
Health SLT	18.723	6.628	14.788	10.563
Life without profit sharing	(14.909)	11.248	(13.048)	9.387
Unit Linked	705.582	27.239	(5.673)	738.494
Total	**709.196**	**45.403**	**(6.200)**	**760.799**

In calculating the actuarial and other policyholder liabilities, various assumptions have been made regarding the future experience of the Company's portfolio of insured risks.

In practice best estimate assumptions represent the most likely outcome as determined by the actuary based on Company and industry experience and other external factors (where appropriate), removing all possible a priori bias on an estimation of the future. Future management actions are also taken into consideration when setting the assumptions (e.g. known future costs).

The main assumptions in assessing the best estimate reserves are as follows:

Interest rates

The risk-free interest rate term structure used for discounting the projected cash flows in the technical calculation is the euro relevant risk-free structure as specified by the Solvency II regulations. The Company used the rates as provided by the EIOPA. The Company did not use the matching adjustment nor the volatility adjustment on 31 December 2025.

Expenses

The expenses incurred in servicing all recognized insurance obligations consist of:

- Administration expenses
- Investment management expenses
- Claims management expenses / handling expenses
- Acquisition expenses
- Overhead expenses

To derive the best estimate expense assumptions, the Company performs an expense analysis on an annual basis. The exercise is based on relevant and available past data, subject to expert judgment, and allows for the Company's budgeted expenses. The purpose of this exercise is to allocate expenses into initial and renewal and provide the necessary split into the various expense categories.

Inflation

The inflation assumption is also very important as it directly impacts on the renewal expenses of the Company (an important source of outflow) as well as the administration fee (which is an important source of income for the Company). In deriving a long-term inflation assumption, the Company looks at long term inflation forecasts and ignores any short-term fluctuations. The assumption is determined by considering both market-based price and services inflation as well as Company specific expenses, such as salaries. Expected future trends are also considered. Together with the expense assumption, it determines the future expense outflows of the Company.

Lapse assumptions

Lapse assumptions are set with reference to the Company's experience of policyholder behavior and the prospective assessment of expected policyholder behavior.

Policyholders' option to lapse and in certain cases to surrender are mainly dependent on the change of policyholders' status such as the ability to further pay the premium, employment status, family status etc.

Lapse assumptions vary by type of business and policy year.

Mortality

In determining the mortality assumption, the Company should use appropriate data that reflects the Company's expected future mortality experience. Since the Company does not have sufficient data to develop its own table, the Company creates its own table by applying a percentage on a standard mortality table. The assumed percentage is determined based on past internal data allowing for expert judgment.

Level of uncertainty associated with the value of technical provisions

Uncertainty relates primarily to the extent that future actual experience will deviate from the best estimate assumptions used in the calculation of the technical provisions. The key assumptions which usually give rise to the higher level of uncertainty are interest rates, lapse rates and mortality rates. A robust assumption setting process is followed to ensure that the uncertainty is well understood.

Solvency II and IFRS Accounting Standards valuation differences

Whilst Solvency II and IFRS Accounting Standards often use similar approaches and techniques, their most important differences (in terms of methodologies and assumptions) are outlined below:

- The Risk Margin under Solvency II is calculated using a prescribed Cost of Capital basis with the application of a simplification method whereas under IFRS the Risk Adjustment is calculated using a hybrid of Cost of Capital and Value At Risk methodologies.
- Under Solvency II, the discount curve used is based on EIOPA provided term structure whereas IFRS 17 requires the use of a liability discount curve which includes an illiquidity premium (ILP). Therefore, the Company uses the risk-free interest rate curve prescribed by EIOPA plus an ILP which is based on the actual bond portfolio of the Company.
- Under IFRS Accounting Standards, only expenses which are directly attributable should be reflected in the liability measurement whereas under Solvency II all expenses should be allowed for in the calculation of Technical Provisions.
- IFRS Accounting Standards liabilities include the Contractual Service Margin and this component does not exist under Solvency II. This is because Solvency II focuses on measurement of the balance sheet at a point in time, while IFRS 17 is based on a 'roll-forward' approach.

The table below compares the IFRS Accounting Standards valuation of insurance contract liabilities to the Solvency II technical provisions, split by line of business.

Technical provisions (Net of Reinsurance)	Solvency II (BE + RM - RI)	IFRS Accounting Standards valuation	Difference
31.12.2025	**€'000**	**€'000**	**€'000**
Health Non SLT	4.223	2.776	1.447
Health SLT	5.620	(30.018)	35.638
Life excluding unit linked	15.871	29.956	(14.085)
Unit Linked	875.582	917.314	(41.732)
Total	**901.296**	**920.028**	**(18.732)**

Technical provisions (Net of Reinsurance)	Solvency II (BE + RM - RI)	IFRS Accounting Standards valuation	Difference
31.12.2024	**€'000**	**€'000**	**€'000**
Health Non SLT	2.355	2.043	312
Health SLT	10.563	706	9.857
Life excluding unit-linked	9.387	6.398	2.989
Unit Linked	738.494	757.877	(19.383)
Total	**760.799**	**767.024**	**(6.225)**

D.3 Liabilities (other than technical provisions)

The primary objective of liabilities (other than technical provisions) valuation for Solvency purposes is set out in Article 75 of the Solvency II Directive which requires an economic, market-consistent approach to the valuation of liabilities (other than technical provisions). According to this approach liabilities (other than technical provisions) should be valued at the amount for which they could be transferred, or settled, between knowledgeable willing parties in an arm's length transaction. The default reference framework for valuing liabilities (other than technical provisions) is the IFRS Accounting Standards as adopted by the European Union. The Company's financial statements are prepared in accordance with IFRS Accounting Standards and contain a summary of the significant accounting policies adopted in their preparation.

The following table summarises for each material class of liabilities (other than technical provisions), the value of the liability (other than technical provisions) and a description for the bases, methods and main assumptions used for valuation for solvency purposes.

Liabilities	Value	Value	Solvency II valuation basis
	31.12.2025 €'000	**31.12.2024 €'000**	
Deferred tax liabilities	6.283	3.511	Measured at the amount that is expected to be paid to the tax authorities after considering the tax rates and legislation that have been enacted or substantially been enacted by the reporting date. The Solvency II balance sheet includes a deferred tax liability arising on reporting differences from the change in technical provisions under Solvency II.
Insurance & intermediaries payables	37.314	33.244	Includes amounts due to policyholders, amounts due to agents, the current account with the reinsurer and the outstanding claims incurred. Valued on the same basis as per IFRS Accounting Standards financial statements.
Reinsurance payables	1.557	66	Valued on the same basis as per IFRS Accounting Standards financial statements.
Payables (trade, not insurance)	17.606	11.708	Valued on the same basis as per IFRS Accounting Standards financial statements.
Any other liabilities, not elsewhere shown	2.717	964	Valued on the same basis as per IFRS Accounting Standards financial statements.
Total liabilities	**65.477**	**49.493**	

The Solvency II balance sheet includes a deferred tax liability arising from the temporary differences between technical provisions under Solvency II compared to those under IFRS (which are not used for income tax purposes).

D.4 Other

There are no other material matters in respect to the valuation of assets and liabilities for solvency purposes.

E. Capital Management

E. Capital Management

E.1 Own Funds

The objective of own funds management is to maintain, at all times, sufficient own funds to cover the SCR and MCR with an appropriate buffer. These should be of sufficient quality to meet the eligibility requirements of Article 82 of the Delegated Regulation. The Company's Actuarial and Finance functions hold regular meetings during which the ratio of eligible own funds over SCR and MCR are reviewed. The ultimate responsibility rests with the Company's Board of Directors. As part of own funds management, the Company undertakes an ORSA exercise at least annually. The ORSA exercise incorporates the business planning process which is typically considered over a three-year time horizon.

The merger of Eurolife with ex-Ethniki affected the Company's capital structure as follows:

Own Funds: they were updated to reflect the recognition of transferred net assets and liabilities from Ethniki Insurance (Cyprus) Ltd, adjusted for any ineligible items under Solvency II.

SCR: this was recalculated to reflect expanded underwriting, market and counterparty risks arising from the merged business.

MCR: increased in line with the higher volume of technical provisions and new lines of business.

These capital impacts are disclosed in accordance with Solvency II solo capital management transparency requirements.

An analysis of own funds by tier is shown below:

	Ordinary Share capital	Share Premium	Reconciliation reserve	Total
	€'000	**€'000**	**€'000**	**€'000**
1 January 2024	**15.647**	**-**	**79.382**	**95.029**
Movement for the year	-	-	18.342	18.342
31 December 2024	**15.647**	**-**	**97.724**	**113.371**
Movement for the year	3	18.343	20.644	38.990
31 December 2025	**15.650**	**18.343**	**118.368**	**152.361**
Total Basic Own Funds – Tier 1	**15.650**	**18.343**	**118.368**	**152.361**

The Company's ordinary share capital, share premium and reconciliation reserve are all available as tier 1 unrestricted own funds as per Article 69 (a)(i) of the Delegated Regulation. The reconciliation reserve equals the excess of assets over liabilities less other basic own funds as at the reporting date. There are no foreseeable dividends or own shares held.

The Company has no tier 1 restricted own funds (as per Article 80 of the Delegated Regulation), no tier 2 own funds (as per Article 72 of the Delegated Regulation) and no tier 3 own funds (as per Article 76 of the Delegated Regulation). The Company's own funds are all available to cover the SCR and MCR.

The table below shows the difference between own funds as shown in the financial statements and the Solvency II own funds:

	31.12.2025	31.12.2024
	€'000	€'000
Total own funds per Financial Statements	**144.427**	**114.312**
Intangible assets	(7.988)	(6.388)
Change in valuation of Technical Provisions (net)	18.732	6.225
Change in Deferred Tax Liability	(2.810)	(778)
Total Tier 1 Capital	**152.361**	**113.371**
Total basic own funds	**152.361**	**113.371**

E.2 Solvency Capital Requirement and Minimum Capital Requirement

The Company's Solvency Capital Requirement and Minimum Capital Requirement, based on the Solvency II standard formula methodology, for the financial year-end 2025 and 2024 are as follows:

	31.12.2025	31.12.2024
	€'000	€'000
Total available own funds to meet the SCR	152.361	113.371
Solvency Capital Requirement (SCR)	67.469	50.664
Solvency Ratio	**226%**	**224%**
Total available own funds to meet the MCR	152.361	113.371
Minimum Capital Requirement (MCR)	23.755	20.658
Ratio of Eligible own funds to MCR	**641%**	**549%**

The final amount of the SCR and MCR remains subject to supervisory assessment.

A further analysis of the Company's SCR for the year 2025 and 2024 to its different constituents is shown below:

Solvency Capital Requirement (SCR)	31.12.2025	31.12.2024
	€'000	€'000
Market Risk	17.232	13.282
Counterparty Risk	1.653	4.132
Life Underwriting Risk	60.759	41.290
Health Risk	13.320	10.502
Diversification Basic Solvency Capital Requirement (BSCR)	(20.251)	(17.208)
BSCR	**72.713**	**51.998**
Operational Risk	6.663	5.904
Loss Absorbing Capacity for Deferred Tax	(11.907)	(7.238)
SCR Total	**67.469**	**50.664**

It should be noted that simplified calculations are not used for any of the risk modules or sub modules.

The table below shows the inputs into the MCR calculation as at 31 December 2025 and 2024. Note the Absolute Floor of the Minimum Capital Requirement (AMCR) is prescribed by EIOPA and stated in Euros below:

Minimum Capital Requirement (MCR)	31.12.2025	31.12.2024
	€'000	€'000
AMCR	6.700	6.700
Linear MCR	23.755	20.658
SCR	67.469	50.664
Combined MCR	23.755	20.658
MCR	**23.755**	**20.658**

E.3 Non-Compliance with the MCR and Non-Compliance with the SCR

The Company has maintained sufficient capital to meet its MCR and SCR throughout the years 2025 and 2024.

E.4 Other

During 2026, the Company identified parameterisation errors affecting the lapse, expense and morbidity stress calculations. The SCR Model review further identified that the effect of reinsurance as a risk mitigation technique had not been reflected in the calculation of Life and Health Underwriting Risks.

The relevant calculations were corrected, and the Company's solvency position has been recalculated accordingly. The Solvency Ratio as at 31 December 2025 was revised to 226%, compared with the previously reported 281%, while the Solvency Ratio as at 31 December 2024 was revised to 224%, compared with the previously reported 226%.

To ensure the stakeholders have access to accurate and up-to-date information, the Company has reissued this SFCR, subsequent to its submission on 3 April 2026 and 13 August 2026 to provide enhanced disclosures in relation to this matter (including comparatives figures for 2024).

The revision did not affect the Company's compliance with regulatory capital requirements, as the Solvency Ratio remained comfortably above the applicable regulatory minimum requirement of 100%. The Superintendent of Insurance was informed of the matter and imposed an administrative fine of €100.000.

The Company has undertaken a number of corrective and preventive measures to remedy the issue identified, reinforce the accuracy and reliability of its models and mitigate the risk of similar issues arising in the future. In addition, the Company is taking further steps to strengthen its model review, validation and monitoring processes while embedding enhancements across its broader control framework.

F. Glossary

F. Glossary

ALM	Asset Liability Management
BoC	Bank of Cyprus
BoD/Board	Board of Directors
EIOPA	European Insurance and Occupational Pensions Authority
ExCo	Executive Committee
GRMD	Group Risk Management Division
IAS	International Accounting Standards
ICCS	Insurance Companies Control Service
ICS	Internal Control System
IFRS	International Financial Reporting Standards
MCR	Minimum Capital Requirement
NED	Non-Executive Director
Non-SLT Health	Similar to Non-Life Techniques
ORSA	Own Risk and Solvency Assessment
QRTs	Quantitative Reporting Templates
RAS	Risk Appetite and Tolerance Statement
RCSA	Risk and control self-assessment
RMF	Risk Management Function
SCR	Solvency Capital Requirement
SFCR	Solvency and Financial Condition Report
SLT Health obligations	Similar to Life Techniques
SMT	Senior Management Team
UCITS	Undertakings for Collective Investment in Transferable Securities

G. Templates

Templates 2025

Section G
S.02.01.02
Balance sheet

		Solvency II value
Assets		**C0010**
Goodwill	**R0010**	
Deferred acquisition costs	**R0020**	
Intangible assets	**R0030**	
Deferred tax assets	**R0040**	0,00
Pension benefit surplus	**R0050**	3.349.956,59
Property, plant & equipment held for own use	**R0060**	19.739.197,81
Investments (other than assets held for index-linked and unit-linked contracts)	**R0070**	144.835.096,40
Property (other than for own use)	**R0080**	12.055.000,00
Holdings in related undertakings, including participations	**R0090**	
Equities	**R0100**	
Equities - listed	**R0110**	
Equities - unlisted	**R0120**	
Bonds	**R0130**	29.147.547,13
Government Bonds	**R0140**	25.917.618,54
Corporate Bonds	**R0150**	3.229.928,58
Structured notes	**R0160**	
Collateralised securities	**R0170**	
Collective Investments Undertakings	**R0180**	101.726.990,06
Derivatives	**R0190**	
Deposits other than cash equivalents	**R0200**	1.905.559,21
Other investments	**R0210**	
Assets held for index-linked and unit-linked contracts	**R0220**	915.311.002,79
Loans and mortgages	**R0230**	413.573,97
Loans on policies	**R0240**	413.573,97
Loans and mortgages to individuals	**R0250**	0,00
Other loans and mortgages	**R0260**	
Reinsurance recoverables from:	**R0270**	-18.546.825,25
Non-life and health similar to non-life	**R0280**	-2.235.963,10
Non-life excluding health	**R0290**	
Health similar to non-life	**R0300**	-2.235.963,10
Life and health similar to life, excluding health and index-linked and unit-linked	**R0310**	-10.109.850,84
Health similar to life	**R0320**	739.192,61
Life excluding health and index-linked and unit-linked	**R0330**	-10.849.043,45
Life index-linked and unit-linked	**R0340**	-6.201.011,31
Deposits to cedants	**R0350**	
Insurance and intermediaries receivables	**R0360**	5.599.182,44
Reinsurance receivables	**R0370**	8.671.404,14
Receivables (trade, not insurance)	**R0380**	1.410.235,44
Own shares (held directly)	**R0390**	
Amounts due in respect of own fund items or initial fund called up but not yet paid in	**R0400**	
Cash and cash equivalents	**R0410**	4.867.800,46
Any other assets, not elsewhere shown	**R0420**	14.935.520,50
Total assets	**R0500**	1.100.586.145,29
		Solvency II value
Liabilities		**C0010**
Technical provisions - non-life	**R0510**	1.986.496,73
Technical provisions - non-life (excluding health)	**R0520**	
Technical provisions calculated as a whole	**R0530**	
Best Estimate	**R0540**	
Risk margin	**R0550**	
Technical provisions - health (similar to non-life)	**R0560**	1.986.496,73
Technical provisions calculated as a whole	**R0570**	0,00
Best Estimate	**R0580**	1.677.762,35
Risk margin	**R0590**	308.734,38
Technical provisions - life (excluding index-linked and unit-linked)	**R0600**	11.382.006,78
Technical provisions - health (similar to life)	**R0610**	6.359.219,28
Technical provisions calculated as a whole	**R0620**	0,00
Best Estimate	**R0630**	-3.619.943,38
Risk margin	**R0640**	9.979.162,67
Technical provisions - life (excluding health and index-linked and unit-linked)	**R0650**	5.022.787,50
Technical provisions calculated as a whole	**R0660**	0,00
Best Estimate	**R0670**	-10.594.549,69
Risk margin	**R0680**	15.617.337,19
Technical provisions - index-linked and unit-linked	**R0690**	869.380.830,15
Technical provisions calculated as a whole	**R0700**	0,00
Best Estimate	**R0710**	822.821.906,62
Risk margin	**R0720**	46.558.923,53
Other technical provisions	**R0730**	
Contingent liabilities	**R0740**	
Provisions other than technical provisions	**R0750**	
Pension benefit obligations	**R0760**	0,00
Deposits from reinsurers	**R0770**	
Deferred tax liabilities	**R0780**	6.283.169,48
Derivatives	**R0790**	
Debts owed to credit institutions	**R0800**	
Financial liabilities other than debts owed to credit institutions	**R0810**	
Insurance & intermediaries payables	**R0820**	37.313.991,36
Reinsurance payables	**R0830**	1.556.690,82
Payables (trade, not insurance)	**R0840**	17.605.702,82
Subordinated liabilities	**R0850**	
Subordinated liabilities not in Basic Own Funds	**R0860**	
Subordinated liabilities in Basic Own Funds	**R0870**	
Any other liabilities, not elsewhere shown	**R0880**	2.716.281,26
Total liabilities	**R0900**	948.225.169,40
Excess of assets over liabilities	**R1000**	152.360.975,89

Section G
S.05.01.02
Premiums, claims and expenses by line of business

		Line of Business for: non-life insurance and reinsurance obligations (direct business and accepted proportional reinsurance)												Line of business for: accepted non-proportional reinsurance				Total
		Medical expense insurance	Income protection insurance	Workers' compensation insurance	Motor vehicle liability insurance	Other motor insurance	Marine, aviation and transport insurance	Fire and other damage to property insurance	General liability insurance	Credit and suretyship insurance	Legal expenses insurance	Assistance	Miscellaneous financial loss	Health	Casualty	Marine, aviation, transport	Property	
		C0010	C0020	C0030	C0040	C0050	C0060	C0070	C0080	C0090	C0100	C0110	C0120	C0130	C0140	C0150	C0160	C0200
Premiums written																		
Gross - Direct Business	R0110	28.157.960,73																28.157.960,73
Gross - Proportional reinsurance accepted	R0120																	
Gross - Non-proportional reinsurance accepted	R0130																	
Reinsurers' share	R0140	14.307.220,15																14.307.220,15
Net	R0200	13.850.740,58																13.850.740,58
Premiums earned																		
Gross - Direct Business	R0210	27.922.130,62																27.922.130,62
Gross - Proportional reinsurance accepted	R0220																	
Gross - Non-proportional reinsurance accepted	R0230																	
Reinsurers' share	R0240	14.157.440,44																14.157.440,44
Net	R0300	13.764.690,18																13.764.690,18
Claims incurred																		
Gross - Direct Business	R0310	11.832.356,06																11.832.356,06
Gross - Proportional reinsurance accepted	R0320																	
Gross - Non-proportional reinsurance accepted	R0330																	
Reinsurers' share	R0340	5.755.440,50																5.755.440,50
Net	R0400	6.076.915,56																6.076.915,56
Expenses incurred	R0550	10.016.120,78																10.016.120,78
Balance - other technical expenses/income	R1210																	
Total technical expenses	R1300																	10.016.120,78

		Line of Business for: life insurance obligations						Life reinsurance obligations		Total
		Health insurance	Insurance with profit participation	Index-linked and unit-linked insurance	Other life insurance	Annuities stemming from non-life insurance contracts and relating to health insurance obligations	Annuities stemming from non-life insurance contracts and relating to insurance obligations other than health insurance obligations	Health reinsurance	Life reinsurance	
		C0210	C0220	C0230	C0240	C0250	C0260	C0270	C0280	C0300
Premiums written										
Gross	R1410	9.719.609,92		195.804.819,92	23.921.241,28					229.445.671,12
Reinsurers' share	R1420	7.123.441,40		6.066.179,89	8.573.495,04					21.763.116,33
Net	R1500	2.596.168,52		189.738.640,03	15.347.746,24					207.682.554,79
Premiums earned										
Gross	R1510	9.719.609,92		195.804.819,92	23.921.241,28					229.445.671,12
Reinsurers' share	R1520	7.123.441,40		6.066.179,89	8.573.495,04					21.763.116,33
Net	R1600	2.596.168,52		189.738.640,03	15.347.746,24					207.682.554,79
Claims incurred										
Gross	R1610	-6.475,00		86.511.927,35	5.111.557,80					91.617.010,15
Reinsurers' share	R1620	21.110,00		3.867.755,95	3.195.968,40					7.084.834,35
Net	R1700	-27.585,00		82.644.171,40	1.915.589,40					84.532.175,80
Expenses incurred	R1900	3.714.208,16		36.286.446,34	7.181.820,64					47.182.475,13
Balance - other technical expenses/income	R2510									
Total technical expenses	R2600									47.182.475,13
Total amount of surrenders	R2700			72.457.450,71						72.457.450,71

Section G
S.12.01.02
Life and Health SLT Technical Provisions

		Index-linked and unit-linked insurance				Other life insurance				Accepted reinsurance					Health insurance (direct business)						
		Insurance with profit participation		Contracts without options and guarantees	Contracts with options and guarantees		Contracts without options and guarantees	Contracts with options and guarantees	Annuities stemming from non-life insurance contracts and relating to insurance obligation other than health insurance obligations		Insurance with profit participation on Accepted reinsurance (Gross)	Index-linked and unit-linked insurance on Accepted reinsurance (Gross)	Other life insurance on Accepted reinsurance (Gross)	Annuities stemming from non-life accepted insurance contracts and relating to insurance obligation other than health insurance obligations (Gross)	Total (Life other than health insurance, incl. Unit-Linked)		Contracts without options and guarantees	Contracts with options and guarantees	Annuities stemming from non-life insurance contracts and relating to health insurance obligations	Health reinsurance (reinsurance accepted)	Total (Health similar to life insurance)
		C0020	C0030	C0040	C0050	C0060	C0070	C0080	C0090	C0100	C0110	C0120	C0130	C0140	C0150	C0160	C0170	C0180	C0190	C0200	C0210
Technical provisions calculated as a whole	R0010	0,00	0,00			0,00									0,00	0,00					0,00
Total Recoverables from reinsurance/SPV and Finite Re after the adjustment for expected losses due to counterparty default associated to TP calculated as a whole	R0020	0,00	0,00			0,00									0,00	0,00					0,00
Technical provisions calculated as a sum of BE and RM																					
Best Estimate																					
Gross Best Estimate	R0030	9 794 051,38		769 852 213,26	52 969 693,36		-20 524 927,13	146 326,06							812 227 356,93		-3 619 943,38				-3 619 943,38
Total Recoverables from reinsurance/SPV and Finite Re after the adjustment for expected losses due to counterparty default	R0080	-128 261,13		-6 059 255,94	-701 800,37		-50 806 407,58	85 635,27							-57 050 854,76		749 592,81				749 592,81
Best estimate minus recoverables from reinsurance/SPV and Finite Re	R0090	9 912 312,51		775 801 423,60	53 161 494,33		6 718 519,55	60 690,79							829 277 411,69		-4 358 185,99				-4 358 185,99
Risk Margin	R0100	202 775,58	46 558 923,53			14 915 541,61									61 676 290,72	3 979 162,67					3 979 162,67
Amount of the transitional on Technical Provisions																					
Technical provisions - total	R0200	10 485 826,96	869 380 830,13			-5 463 035,44									874 403 617,34	6 359 219,28					6 359 219,28
Expected profits included in future premiums (EPIFP)	R0270	1 052 543,08	45 386 299,93			0,00									46 438 753,01	0,00					0,00

Section G

S.17.01.02

Non-life Technical Provisions

		Direct business and accepted proportional reinsurance												accepted non-proportional reinsurance			
		Medical expense insurance	Income protection insurance	Workers' compensation insurance	Motor vehicle liability insurance	Other motor insurance	Marine, aviation and transport insurance	Fire and other damage to property insurance	General liability insurance	Credit and suretyship insurance	Legal expenses insurance	Assistance	Miscellaneous financial loss	Non-proportional health reinsurance	Non-proportional casualty reinsurance	Non-proportional marine, aviation and transport reinsurance	Non-proportional property reinsurance
		C0020	C0030	C0040	C0050	C0060	C0070	C0080	C0090	C0100	C0110	C0120	C0130	C0140	C0150	C0160	C0170
Technical provisions calculated as a whole	R0010																
Total Recoverables from reinsurance/SPV and Finite Re after the adjustment for expected losses due to counterparty default associated to TP calculated as a whole	R0050																
Technical provisions calculated as a sum of BE and RM																	
Best estimate																	
Premium provisions																	
Gross - Total	R0060	-1.983.002,12	51.775,29														
Total recoverable from reinsurance/SPV and Finite Re after the adjustment for expected losses due to counterparty default	R0140	-3.110.766,44	0,00														
Net Best Estimate of Premium Provisions	R0150	1.127.764,32	51.775,29														
Claims provisions																	
Gross - Total	R0160	3.479.952,94	129.036,24														
Total recoverable from reinsurance/SPV and Finite Re after the adjustment for expected losses due to counterparty default	R0240	874.319,18	484,15														
Net Best Estimate of Claims Provisions	R0250	2.605.633,76	128.552,08														
Total Best estimate - gross	R0260	1.496.950,83	180.811,53														
Total Best estimate - net	R0270	3.733.398,08	180.327,37														
Risk margin	R0280	305.339,11	3.395,27														
Technical provisions - total	R0320	1.802.289,94	184.206,80														
Recoverable from reinsurance contract/SPV and Finite Re after the adjustment for expected losses due to counterparty default - total	R0330	-2.236.447,25	484,15														
Technical provisions minus recoverables from reinsurance/SPV and Finite Re- total	R0340	4.038.737,19	183.722,64														

Section G
S.19.01.21
Non-life Insurance Claims Information

Line of business	**Z0010**	Medical expense insurance [direct business and accepted proportional reinsurance]
Accident year / Underwriting year	**Z0020**	Accident year [AY]
Currency	**Z0030**	Total/NA
Currency conversion	**Z0040**	Not applicable / Expressed in (converted to) reporting currency

Gross Claims Paid (non-cumulative)
(absolute amount)

Year		0	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15 & +
		C0010	C0020	C0030	C0040	C0050	C0060	C0070	C0080	C0090	C0100	C0110	C0120	C0130	C0140	C0150	C0160
Prior	R0100																
N-14	R0110																
N-13	R0120																
N-12	R0130	7.072.274,18	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00			
N-11	R0140	7.307.777,60	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00				
N-10	R0150	9.931.577,02	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00					
N-9	R0160	8.517.921,73	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00						
N-8	R0170	13.186.325,29	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00							
N-7	R0180	19.594.864,57	0,00	0,00	0,00	0,00	0,00	0,00	0,00								
N-6	R0190	19.355.905,78	0,00	0,00	0,00	0,00	0,00	0,00									
N-5	R0200	13.550.220,19	0,00	0,00	0,00	0,00	0,00										
N-4	R0210	8.842.369,18	0,00	0,00	0,00	0,00											
N-3	R0220	9.953.524,10	0,00	0,00	0,00												
N-2	R0230	11.310.735,48	0,00	0,00													
N-1	R0240	11.006.597,85	0,00														
N	R0250	11.996.117,17															

		In Current year	Sum of years (cumulative)
		C0170	C0180
	R0100		
	R0110		
	R0120		
	R0130	0,00	7.072.274,18
	R0140	0,00	7.307.777,60
	R0150	0,00	9.931.577,02
	R0160	0,00	8.517.921,73
	R0170	0,00	13.186.325,29
	R0180	0,00	19.594.864,57
	R0190	0,00	19.355.905,78
	R0200	0,00	13.550.220,19
	R0210	0,00	8.842.369,18
	R0220	0,00	9.953.524,10
	R0230	0,00	11.310.735,48
	R0240	0,00	11.006.597,85
	R0250	11.996.117,17	11.996.117,17
Total	R0260	11.996.117,17	151.626.210,14

Gross undiscounted Best Estimate Claims Provisions
(absolute amount)

Year		0	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15 & +
		C0200	C0210	C0220	C0230	C0240	C0250	C0260	C0270	C0280	C0290	C0300	C0310	C0320	C0330	C0340	C0350
Prior	R0100																
N-14	R0110																
N-13	R0120																
N-12	R0130																
N-11	R0140																
N-10	R0150																
N-9	R0160																
N-8	R0170																
N-7	R0180																
N-6	R0190																
N-5	R0200																
N-4	R0210																
N-3	R0220																
N-2	R0230																
N-1	R0240																
N	R0250	803.066,16															

		Year end (discounted data)
		C0360
	R0100	
	R0110	
	R0120	
	R0130	
	R0140	
	R0150	
	R0160	
	R0170	
	R0180	
	R0190	
	R0200	
	R0210	
	R0220	
	R0230	
	R0240	
	R0250	803.066,16
Total	R0260	803.066,16

Section G
S.23.01.01
Own funds

		Total	Tier 1 - unrestricted	Tier 1 - restricted	Tier 2	Tier 3
		C0010	C0020	C0030	C0040	C0050
Basic own funds before deduction for participations in other financial sector as foreseen in article 68 of Delegated Regulation 2015/35						
Ordinary share capital (gross of own shares)	R0010	15.649.920,00	15.649.920,00			
Share premium account related to ordinary share capital	R0030	18.343.012,64	18.343.012,64			
Iinitial funds, members' contributions or the equivalent basic own - fund item for mutual and mutual-type undertakings	R0040					
Subordinated mutual member accounts	R0050					
Surplus funds	R0070					
Preference shares	R0090					
Share premium account related to preference shares	R0110					
Reconciliation reserve	R0130	118.368.043,25	118.368.043,25			
Subordinated liabilities	R0140					
An amount equal to the value of net deferred tax assets	R0160	0,00				0,00
Other own fund items approved by the supervisory authority as basic own funds not specified above	R0180					
Own funds from the financial statements that should not be represented by the reconciliation reserve and do not meet the criteria to be classified as Solvency II own funds						
Own funds from the financial statements that should not be represented by the reconciliation reserve and do not meet the criteria to be classified as Solvency II own funds	R0220					
Deductions						
Deductions for participations in financial and credit institutions	R0230					
Total basic own funds after deductions	R0290	152.360.975,89	152.360.975,89			0,00
Ancillary own funds						
Unpaid and uncalled ordinary share capital callable on demand	R0300					
Unpaid and uncalled initial funds, members' contributions or the equivalent basic own fund item for mutual and mutual - type undertakings, callable on demand	R0310					
Unpaid and uncalled preference shares callable on demand	R0320					
A legally binding commitment to subscribe and pay for subordinated liabilities on demand	R0330					
Letters of credit and guarantees under Article 96(2) of the Directive 2009/138/EC	R0340					
Letters of credit and guarantees other than under Article 96(2) of the Directive 2009/138/EC	R0350					
Supplementary members calls under first subparagraph of Article 96(3) of the Directive 2009/138/EC	R0360					
Supplementary members calls - other than under first subparagraph of Article 96(3) of the Directive 2009/138/EC	R0370					
Other ancillary own funds	R0390					

		Total	Tier 1 - unrestricted	Tier 1 - restricted	Tier 2	Tier 3
		C0010	C0020	C0030	C0040	C0050
Total ancillary own funds	R0400					
Available and eligible own funds						
Total available own funds to meet the SCR	R0500	152.360.975,89	152.360.975,89			0,00
Total available own funds to meet the MCR	R0510	152.360.975,89	152.360.975,89			
Total eligible own funds to meet the SCR	R0540	152.360.975,89	152.360.975,89	0,00	0,00	0,00
Total eligible own funds to meet the MCR	R0550	152.360.975,89	152.360.975,89	0,00	0,00	
SCR	R0580	67.469.261,19				
MCR	R0600	23.755.018,47				
Ratio of Eligible own funds to SCR	R0620	2,26				
Ratio of Eligible own funds to MCR	R0640	6,41				

		Value
		C0060
Reconciliation reserve		
Excess of assets over liabilities	R0700	152.360.975,89
Own shares (held directly and indirectly)	R0710	
Foreseeable dividends, distributions and charges	R0720	
Other basic own fund items	R0730	33.992.932,64
Adjustment for restricted own fund items in respect of matching adjustment portfolios and ring fenced funds	R0740	0,00
Reconciliation reserve	R0760	118.368.043,25
Expected profits		
Expected profits included in future premiums (EPIFP) - Life business	R0770	46.438.753,01
Expected profits included in future premiums (EPIFP) - Non- life business	R0780	
Total Expected profits included in future premiums (EPIFP)	R0790	46.438.753,01

Section G
S.25.01.21
Solvency Capital Requirement - for undertakings on Standard Formula

Article 112	**Z0010**	No

		Net solvency capital requirement	USP	Simplifications
		C0030	C0040	C0050
Market risk	**R0010**	17.231.761,93		
Counterparty default risk	**R0020**	1.653.252,14		
Life underwriting risk	**R0030**	60.758.985,69	60.758.985,69	
Health underwriting risk	**R0040**	13.320.023,76	13.320.023,76	
Non-life underwriting risk	**R0050**			
Diversification	**R0060**	-20.251.331,40		
Intangible asset risk	**R0070**	0,00		
Basic Solvency Capital Requirement	**R0100**	72.712.692,11		

Calculation of Solvency Capital Requirement		C0100
Adjustment due to RFF/MAP nSCR aggregation	**R0120**	0,00
Operational risk	**R0130**	6.662.909,29
Loss-absorbing capacity of technical provisions	**R0140**	0,00
Loss-absorbing capacity of deferred taxes	**R0150**	-11.906.340,21
Capital requirement for business operated in accordance with Art. 4 of Directive 2003/41/EC	**R0160**	
Solvency Capital Requirement excluding capital add-on	**R0200**	67.469.261,19
Capital add-on already set	**R0210**	
of which, capital add-ons already set - Article 37 (1) Type a	**R0211**	
of which, capital add-ons already set - Article 37 (1) Type b	**R0212**	
of which, capital add-ons already set - Article 37 (1) Type c	**R0213**	
of which, capital add-ons already set - Article 37 (1) Type d	**R0214**	
Solvency capital requirement	**R0220**	67.469.261,19
Other information on SCR		
Capital requirement for duration-based equity risk sub-module	**R0400**	
Total amount of Notional Solvency Capital Requirements for remaining part	**R0410**	
Total amount of Notional Solvency Capital Requirements for ring-fenced funds	**R0420**	0,00
Total amount of Notional Solvency Capital Requirements for matching adjustment portfolios	**R0430**	0,00
Diversification effects due to RFF nSCR aggregation for article 304	**R0440**	0,00

Approach to tax rate		C0109
Approach based on average tax rate	**R0590**	Approach based on average tax rate

		LAC DT C0130
LAC DT	**R0640**	-11.906.340,21
LAC DT justified by reversion of deferred tax liabilities	**R0650**	0,00
LAC DT justified by reference to probable future taxable economic profit	**R0660**	-11.906.340,21
LAC DT justified by carry back, current year	**R0670**	0,00
LAC DT justified by carry back, future years	**R0680**	0,00
Maximum LAC DT	**R0690**	-7.937.560,14

Section G

S.28.02.01

Minimum Capital Requirement - Both life and non-life insurance activity

		Non-life activities	Life activities
		MCR(NL, NL) Result	MCR(NL, L)Result
		C0010	C0020
Linear formula component for non-life insurance and reinsurance obligations	R0010	848.872,69	0,00

		Net (of reinsurance/ SPV) best estimate and TP calculated as a whole	Net (of reinsurance) written premiums in the last 12 months	Net (of reinsurance/SPV) best estimate and TP calculated as a whole	Net (of reinsurance) written premiums in the last 12 months
		C0030	C0040	C0050	C0060
Medical expenses and proportional reinsurance	R0020	3.733.398,08	13.850.740,58		
Income protection insurance and proportional reinsurance	R0030	180.327,37	0,00		
Workers' compensation insurance and proportional reinsurance	R0040				
Motor vehicle liability insurance and proportional reinsurance	R0050				
Other motor insurance and proportional reinsurance	R0060				
Marine, aviation and transport insurance and proportional reinsurance	R0070				
Fire and other damage to property insurance and proportional reinsurance	R0080				
General liability insurance and proportional reinsurance	R0090				
Credit and suretyship insurance and proportional reinsurance	R0100				
Legal expenses insurance and proportional reinsurance	R0110				
Assistance and proportional reinsurance	R0120				
Miscellaneous financial loss insurance and proportional reinsurance	R0130				
Non-proportional health reinsurance	R0140				
Non-proportional casualty reinsurance	R0150				
Non-proportional marine, aviation and transport reinsurance	R0160				
Non-proportional property reinsurance	R0170				

		Non-life activities	Life activities
		MCR(L, NL) Result	MCR(L, L) Result
		C0070	C0080
Linear formula component for life insurance and reinsurance obligations	R0200	0,00	22.906.145,77

		Net (of reinsurance/SPV) best estimate and TP calculated as a whole	Net (of reinsurance/SPV) total capital at risk	Net (of reinsurance/SPV) best estimate and TP calculated as a whole	Net (of reinsurance/SPV) total capital at risk
		C0090	C0100	C0110	C0120
Obligations with profit participation - guaranteed benefits	R0210			0,00	
Obligations with profit participation - future discretionary benefits	R0220			0,00	
Index-linked and unit-linked obligations	R0230			829.022.917,93	
Other life (re)insurance and health (re)insurance obligations	R0240			0,00	
Total capital at risk for all life (re)insurance obligations	R0250				24.432.836.213,56

Overall MCR calculation		Value
		C0130
Linear MCR	R0300	23.755.018,47
SCR	R0310	67.469.261,19
MCR cap	R0320	30.361.167,54
MCR floor	R0330	16.867.315,30
Combined MCR	R0340	23.755.018,47
Absolute floor of the MCR	R0350	6.700.000,00
Minimum Capital Requirement	R0400	23.755.018,47

Notional non-life and life MCR calculation		Non-life activities	Life activities
		C0140	C0150
Notional linear MCR	R0500	848.872,69	22.906.145,77
Notional SCR excluding add-on (annual or latest calculation)	R0510	2.410.977,43	65.058.283,77
Notional MCR cap	R0520	1.084.939,84	29.276.227,70
Notional MCR floor	R0530	602.744,36	16.264.570,94
Notional Combined MCR	R0540	848.872,69	22.906.145,77
Absolute floor of the notional MCR	R0550	2.700.000,00	4.000.000,00
Notional MCR	R0560	2.700.000,00	22.906.145,77

Templates 2024

Section G
S.02.01.02
Balance sheet

		Solvency II value
Assets		**C0010**
Goodwill	**R0010**	
Deferred acquisition costs	**R0020**	
Intangible assets	**R0030**	
Deferred tax assets	**R0040**	0,00
Pension benefit surplus	**R0050**	1.766.905,59
Property, plant & equipment held for own use	**R0060**	16.251.620,51
Investments (other than assets held for index-linked and unit-linked contracts)	**R0070**	107.890.536,12
Property (other than for own use)	**R0080**	12.055.000,00
Holdings in related undertakings, including participations	**R0090**	
Equities	**R0100**	
Equities - listed	**R0110**	
Equities - unlisted	**R0120**	
Bonds	**R0130**	15.509.251,92
Government Bonds	**R0140**	10.537.670,20
Corporate Bonds	**R0150**	4.971.581,73
Structured notes	**R0160**	
Collateralised securities	**R0170**	
Collective Investments Undertakings	**R0180**	79.712.873,43
Derivatives	**R0190**	
Deposits other than cash equivalents	**R0200**	613.410,78
Other investments	**R0210**	
Assets held for index-linked and unit-linked contracts	**R0220**	764.595.154,28
Loans and mortgages	**R0230**	348.081,52
Loans on policies	**R0240**	348.081,52
Loans and mortgages to individuals	**R0250**	0,00
Other loans and mortgages	**R0260**	
Reinsurance recoverables from:	**R0270**	-6.200.243,05
Non-life and health similar to non-life	**R0280**	-2.266.607,99
Non-life excluding health	**R0290**	
Health similar to non-life	**R0300**	-2.266.607,99
Life and health similar to life, excluding health and index-linked and unit-linked	**R0310**	1.738.876,57
Health similar to life	**R0320**	14.788.068,73
Life excluding health and index-linked and unit-linked	**R0330**	-13.049.192,16
Life index-linked and unit-linked	**R0340**	-5.672.511,63
Deposits to cedants	**R0350**	
Insurance and intermediaries receivables	**R0360**	5.444.768,40
Reinsurance receivables	**R0370**	6.729.950,94
Receivables (trade, not insurance)	**R0380**	487.589,42
Own shares (held directly)	**R0390**	
Amounts due in respect of own fund items or initial fund called up but not yet paid in	**R0400**	
Cash and cash equivalents	**R0410**	11.240.962,73
Any other assets, not elsewhere shown	**R0420**	8.907.455,53
Total assets	**R0500**	917.462.782,00
		Solvency II value
Liabilities		**C0010**
Technical provisions - non-life	**R0510**	87.681,82
Technical provisions - non-life (excluding health)	**R0520**	
Technical provisions calculated as a whole	**R0530**	
Best Estimate	**R0540**	
Risk margin	**R0550**	
Technical provisions - health (similar to non-life)	**R0560**	87.681,82
Technical provisions calculated as a whole	**R0570**	0,00
Best Estimate	**R0580**	-200.469,37
Risk margin	**R0590**	288.151,19
Technical provisions - life (excluding index-linked and unit-linked)	**R0600**	21.689.663,06
Technical provisions - health (similar to life)	**R0610**	25.350.184,24
Technical provisions calculated as a whole	**R0620**	0,00
Best Estimate	**R0630**	18.722.553,78
Risk margin	**R0640**	6.627.630,46
Technical provisions - life (excluding health and index-linked and unit-linked)	**R0650**	-3.660.521,18
Technical provisions calculated as a whole	**R0660**	0,00
Best Estimate	**R0670**	-14.908.586,17
Risk margin	**R0680**	11.248.064,99
Technical provisions - index-linked and unit-linked	**R0690**	732.821.010,38
Technical provisions calculated as a whole	**R0700**	0,00
Best Estimate	**R0710**	705.581.671,14
Risk margin	**R0720**	27.239.339,25
Other technical provisions	**R0730**	
Contingent liabilities	**R0740**	
Provisions other than technical provisions	**R0750**	
Pension benefit obligations	**R0760**	0,00
Deposits from reinsurers	**R0770**	
Deferred tax liabilities	**R0780**	3.510.780,64
Derivatives	**R0790**	
Debts owed to credit institutions	**R0800**	
Financial liabilities other than debts owed to credit institutions	**R0810**	
Insurance & intermediaries payables	**R0820**	33.243.664,99
Reinsurance payables	**R0830**	65.851,13
Payables (trade, not insurance)	**R0840**	11.708.523,88
Subordinated liabilities	**R0850**	
Subordinated liabilities not in Basic Own Funds	**R0860**	
Subordinated liabilities in Basic Own Funds	**R0870**	
Any other liabilities, not elsewhere shown	**R0880**	964.433,38
Total liabilities	**R0900**	804.091.609,28
Excess of assets over liabilities	**R1000**	113.371.172,72

Section G
S.05.01.02
Premiums, claims and expenses by line of business

		Line of Business for: non-life insurance and reinsurance obligations (direct business and accepted proportional reinsurance)												Line of business for: accepted non-proportional reinsurance				Total
		Medical expense insurance	Income protection insurance	Workers' compensation	Motor vehicle liability insurance	Other motor insurance	Marine, aviation and transport	Fire and other damage to	General liability insurance	Credit and suretyship insurance	Legal expenses insurance	Assistance	Miscellaneous financial loss	Health	Casualty	Marine, aviation, transport	Property	
		C0010	C0020	C0030	C0040	C0050	C0060	C0070	C0080	C0090	C0100	C0110	C0120	C0130	C0140	C0150	C0160	C0200
Premiums written																		
Gross - Direct Business	**R0110**	27.033.257,07																27.033.257,07
Gross - Proportional reinsurance accepted	**R0120**																	
Gross - Non-proportional reinsurance accepted	**R0130**																	
Reinsurers' share	**R0140**	13.668.635,94																13.668.635,94
Net	**R0200**	13.364.621,13																13.364.621,13
Premiums earned																		
Gross - Direct Business	**R0210**	26.727.557,52																26.727.557,52
Gross - Proportional reinsurance accepted	**R0220**																	
Gross - Non-proportional reinsurance accepted	**R0230**																	
Reinsurers' share	**R0240**	13.506.088,34																13.506.088,34
Net	**R0300**	13.221.469,18																13.221.469,18
Claims incurred																		
Gross - Direct Business	**R0310**	10.920.870,63																10.920.870,63
Gross - Proportional reinsurance accepted	**R0320**																	
Gross - Non-proportional reinsurance accepted	**R0330**																	
Reinsurers' share	**R0340**	5.291.674,97																5.291.674,97
Net	**R0400**	5.629.195,66																5.629.195,66
Expenses incurred	**R0550**	9.784.850,01																9.784.850,01
Balance - other technical expenses/income	**R1210**																	
Total technical expenses	**R1300**																	9.784.850,01

		Line of Business for: life insurance obligations						Life reinsurance obligations		Total
		Health insurance	Insurance with profit	Index-linked and unit-linked	Other life insurance	Annuities stemming from non-	Annuities stemming from non-	Health reinsurance	Life reinsurance	
		C0210	C0220	C0230	C0240	C0250	C0260	C0270	C0280	C0300
Premiums written										
Gross	**R1410**	9.122.576,44		167.790.828,04	22.249.195,54					199.162.600,02
Reinsurers' share	**R1420**	6.772.798,33		5.814.359,27	7.777.749,76					20.364.907,36
Net	**R1500**	2.349.778,11		161.976.468,77	14.471.445,78					178.797.692,66
Premiums earned										
Gross	**R1510**	9.122.576,44		167.790.828,04	22.249.195,54					199.162.600,02
Reinsurers' share	**R1520**	6.772.798,33		5.814.359,27	7.777.749,76					20.364.907,36
Net	**R1600**	2.349.778,11		161.976.468,77	14.471.445,78					178.797.692,66
Claims incurred										
Gross	**R1610**	289.224,67		77.069.453,25	3.315.836,44					80.674.514,36
Reinsurers' share	**R1620**	140.853,00		1.850.609,75	1.549.620,30					3.541.083,05
Net	**R1700**	148.371,67		75.218.843,50	1.766.216,14					77.133.431,31
Expenses incurred	**R1900**	3.735.593,50		31.036.952,14	6.774.329,22					41.546.874,86
Balance - other technical expenses/income	**R2510**									
Total technical expenses	**R2600**									41.546.874,86
Total amount of surrenders	**RZ700**			64.940.974,37						64.940.974,37

Section G
S.12.01.02
Life and Health SLT Technical Provisions

		Index-linked and unit-linked insurance			Other life insurance				Accepted reinsurance						Health insurance (direct business)					
		Insurance with profit participation		Contracts without options and guarantees	Contracts with options and guarantees		Contracts without options and guarantees	Contracts with options and guarantees	Annuities stemming from non-life insurance contracts and relating to insurance obligation other than health insurance obligations		Insurance with profit participation on Accepted reinsurance (Gross)	Index-linked and unit-linked insurance on Accepted reinsurance (Gross)	Other life insurance on Accepted reinsurance (Gross)	Annuities stemming from non-life accepted insurance contracts and relating to insurance obligation other than health insurance obligations (Gross)	Total (Life other than health insurance, incl. Unit-Linked)		Contracts without options and guarantees	Contracts with options and guarantees	Annuities stemming from non-life insurance contracts and relating to health insurance obligations	Health reinsurance (reinsurance accepted)	Total (Health similar to life insurance)
		C0020	C0030	C0040	C0050	C0060	C0070	C0080	C0090	C0100	C0110	C0120	C0130	C0140	C0150	C0160	C0170	C0180	C0190	C0200	C0210
Technical provisions calculated as a whole	**R0010**		0,00			0,00									0,00	0,00					0,00
Total Recoverables from reinsurance/SPV and Finite Re after the adjustment for expected losses due to counterparty default associated to TP calculated as a whole	**R0020**		0,00			0,00									0,00	0,00					0,00
Technical provisions calculated as a sum of BE and RM																					
Best Estimate																					
Gross Best Estimate	**R0030**			672.866.430,79	32.715.240,35		-14.908.586,17								690.673.084,97		18.722.553,78				18.722.553,78
Total Recoverables from reinsurance/SPV and Finite Re after the adjustment for expected losses due to counterparty default	**R0080**			-5.672.511,63			-13.049.192,16								-18.721.703,79		14.788.068,73				14.788.068,73
Best estimate minus recoverables from reinsurance/SPV and Finite Re	**R0090**			678.538.942,42	32.715.240,35		-1.859.394,01								709.394.788,76		3.934.485,04				3.934.485,04
Risk Margin	**R0100**		27.239.339,25			11.248.064,99									38.487.404,24	6.627.630,46					6.627.630,46
Technical provisions - total	**R0200**		732.821.010,38			-3.660.521,18									729.160.489,20	25.350.184,24					25.350.184,24
Expected profits included in future premiums (EPIFP)	**R0370**		16.705.941,95			0,00									16.705.941,95	0,00					0,00

Section G

S.17.01.02

Non-life Technical Provisions

		Direct business and accepted proportional reinsurance												accepted non-proportional reinsurance			
		Medical expense insurance	Income protection insurance	Workers' compensation insurance	Motor vehicle liability insurance	Other motor insurance	Marine, aviation and transport insurance	Fire and other damage to property insurance	General liability insurance	Credit and suretyship insurance	Legal expenses insurance	Assistance	Miscellaneous financial loss	Non-proportional health reinsurance	Non-proportional casualty reinsurance	Non-proportional marine, aviation and transport reinsurance	Non-proportional property reinsurance
		C0020	C0030	C0040	C0050	C0060	C0070	C0080	C0090	C0100	C0110	C0120	C0130	C0140	C0150	C0160	C0170
Technical provisions calculated as a whole	R0010																
Total Recoverables from reinsurance/SPV and Finite Re after the adjustment for expected losses due to counterparty default associated to TP calculated as a whole	R0050																
Technical provisions calculated as a sum of BE and RM																	
Best estimate																	
Premium provisions																	
Gross - Total	R0060	-2.508.037,24															
Total recoverable from reinsurance/SPV and Finite Re after the adjustment for expected losses due to counterparty default	R0140	-3.014.991,13															
Net Best Estimate of Premium Provisions	R0150	506.953,89															
Claims provisions																	
Gross - Total	R0160	2.307.567,87															
Total recoverable from reinsurance/SPV and Finite Re after the adjustment for expected losses due to counterparty default	R0240	748.383,14															
Net Best Estimate of Claims Provisions	R0250	1.559.184,73															
Total Best estimate - gross	R0260	-200.469,37															
Total Best estimate - net	R0270	2.066.138,62															
Risk margin	R0280	288.151,19															
Technical provisions - total	R0320	87.681,82															
Recoverable from reinsurance contract/SPV and Finite Re after the adjustment for expected losses due to counterparty default - total	R0330	-2.266.607,99															
Technical provisions minus recoverables from reinsurance/SPV and Finite Re- total	R0340	2.354.289,81															

Section G
S.19.01.21
Non-life Insurance Claims Information

Line of business	**Z0010**	Medical expense insurance [direct business and accepted proportional reinsurance]
Accident year / Underwriting year	**Z0020**	Accident year [AY]
Currency	**Z0030**	Total/NA
Currency conversion	**Z0040**	Not applicable / Expressed in (converted to) reporting currency

Gross Claims Paid (non-cumulative)
(absolute amount)

Year		0	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15 & +
		C0010	C0020	C0030	C0040	C0050	C0060	C0070	C0080	C0090	C0100	C0110	C0120	C0130	C0140	C0150	C0160
Prior	R0100																
N-14	R0110																
N-13	R0120																
N-12	R0130	7.960.035,47	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00			
N-11	R0140	7.072.274,18	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00				
N-10	R0150	7.307.777,60	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00					
N-9	R0160	9.931.577,02	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00						
N-8	R0170	8.517.921,73	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00							
N-7	R0180	13.186.325,29	0,00	0,00	0,00	0,00	0,00	0,00	0,00								
N-6	R0190	19.594.864,57	0,00	0,00	0,00	0,00	0,00	0,00									
N-5	R0200	19.355.905,78	0,00	0,00	0,00	0,00	0,00										
N-4	R0210	13.550.220,19	0,00	0,00	0,00	0,00											
N-3	R0220	8.842.369,18	0,00	0,00	0,00												
N-2	R0230	9.953.524,16	0,00	0,00													
N-1	R0240	11.310.735,48	0,00														
N	R0250	10.897.248,02															

		In Current year	Sum of years (cumulative)
		C0170	C0180
	R0100		
	R0110		
	R0120		
	R0130	0,00	7.960.035,47
	R0140	0,00	7.072.274,18
	R0150	0,00	7.307.777,60
	R0160	0,00	9.931.577,02
	R0170	0,00	8.517.921,73
	R0180	0,00	13.186.325,29
	R0190	0,00	19.594.864,57
	R0200	0,00	19.355.905,78
	R0210	0,00	13.550.220,19
	R0220	0,00	8.842.369,18
	R0230	0,00	9.953.524,16
	R0240	0,00	11.310.735,48
	R0250	10.897.248,02	10.897.248,02
Total	R0260	10.897.248,02	147.480.778,67

Gross undiscounted Best Estimate Claims Provisions
(absolute amount)

Year		0	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15 & +
		C0200	C0210	C0220	C0230	C0240	C0250	C0260	C0270	C0280	C0290	C0300	C0310	C0320	C0330	C0340	C0350
Prior	R0100																
N-14	R0110																
N-13	R0120																
N-12	R0130																
N-11	R0140																
N-10	R0150																
N-9	R0160																
N-8	R0170																
N-7	R0180																
N-6	R0190																
N-5	R0200																
N-4	R0210																
N-3	R0220																
N-2	R0230																
N-1	R0240																
N	R0250																

		Year end (discounted data)
		C0360
	R0100	
	R0110	
	R0120	
	R0130	
	R0140	
	R0150	
	R0160	
	R0170	
	R0180	
	R0190	
	R0200	
	R0210	
	R0220	
	R0230	
	R0240	
	R0250	
Total	R0260	

Section G
S.23.01.01
Own funds

		Total	Tier 1 - unrestricted	Tier 1 - restricted	Tier 2	Tier 3
		C0010	C0020	C0030	C0040	C0050
Basic own funds before deduction for participations in other financial sector as foreseen in article 68 of Delegated Regulation 2015/35						
Ordinary share capital (gross of own shares)	R0010	15.646.500,00	15.646.500,00			
Share premium account related to ordinary share capital	R0030					
Iinitial funds, members' contributions or the equivalent basic own - fund item for mutual and mutual-type undertakings	R0040					
Subordinated mutual member accounts	R0050					
Surplus funds	R0070					
Preference shares	R0090					
Share premium account related to preference shares	R0110					
Reconciliation reserve	R0130	97.724.672,72	97.724.672,72			
Subordinated liabilities	R0140					
An amount equal to the value of net deferred tax assets	R0160	0,00				0,00
Other own fund items approved by the supervisory authority as basic own funds not specified above	R0180					
Own funds from the financial statements that should not be represented by the reconciliation reserve and do not meet the criteria to be classified as Solvency II own funds						
Own funds from the financial statements that should not be represented by the reconciliation reserve and do not meet the criteria to be classified as Solvency II own funds	R0220					
Deductions						
Deductions for participations in financial and credit institutions	R0230					
Total basic own funds after deductions	R0290	113.371.172,72	113.371.172,72			0,00
Ancillary own funds						
Unpaid and uncalled ordinary share capital callable on demand	R0300					
Unpaid and uncalled initial funds, members' contributions or the equivalent basic own fund item for mutual and mutual - type undertakings, callable on demand	R0310					
Unpaid and uncalled preference shares callable on demand	R0320					
A legally binding commitment to subscribe and pay for subordinated liabilities on demand	R0330					
Letters of credit and guarantees under Article 96(2) of the Directive 2009/138/EC	R0340					
Letters of credit and guarantees other than under Article 96(2) of the Directive 2009/138/EC	R0350					
Supplementary members calls under first subparagraph of Article 96(3) of the Directive 2009/138/EC	R0360					
Supplementary members calls - other than under first subparagraph of Article 96(3) of the Directive 2009/138/EC	R0370					
Other ancillary own funds	R0390					

		Total	Tier 1 - unrestricted	Tier 1 - restricted	Tier 2	Tier 3
		C0010	C0020	C0030	C0040	C0050
Total ancillary own funds	R0400					
Available and eligible own funds						
Total available own funds to meet the SCR	R0500	113.371.172,72	113.371.172,72			0,00
Total available own funds to meet the MCR	R0510	113.371.172,72	113.371.172,72			
Total eligible own funds to meet the SCR	R0540	113.371.172,72	113.371.172,72	0,00	0,00	0,00
Total eligible own funds to meet the MCR	R0550	113.371.172,72	113.371.172,72	0,00	0,00	
SCR	R0580	50.664.488,98				
MCR	R0600	20.657.824,78				
Ratio of Eligible own funds to SCR	R0620	2,24				
Ratio of Eligible own funds to MCR	R0640	5,49				

		Value
		C0060
Reconciliation reserve		
Excess of assets over liabilities	R0700	113.371.172,72
Own shares (held directly and indirectly)	R0710	
Foreseeable dividends, distributions and charges	R0720	
Other basic own fund items	R0730	15.646.500,00
Adjustment for restricted own fund items in respect of matching adjustment portfolios and ring fenced funds	R0740	0,00
Reconciliation reserve	R0760	97.724.672,72
Expected profits		
Expected profits included in future premiums (EPIFP) - Life business	R0770	16.705.941,95
Expected profits included in future premiums (EPIFP) - Non- life business	R0780	
Total Expected profits included in future premiums (EPIFP)	R0790	16.705.941,95

Section G
S.25.01.21
Solvency Capital Requirement - for undertakings on Standard Formula

Article 112	**Z0010**	No

		Net solvency capital requirement	USP	Simplifications
		C0030	C0040	C0050
Market risk	R0010	13.282.116,73		
Counterparty default risk	R0020	4.131.649,28		
Life underwriting risk	R0030	41.289.536,82	41.289.536,82	0,00
Health underwriting risk	R0040	10.501.516,59	10.501.516,59	0,00
Non-life underwriting risk	R0050			
Diversification	R0060	-17.207.017,57		
Intangible asset risk	R0070	0,00		
Basic Solvency Capital Requirement	R0100	51.997.801,84		

Calculation of Solvency Capital Requirement		C0100
Adjustment due to RFF/MAP nSCR aggregation	R0120	0,00
Operational risk	R0130	5.904.471,27
Loss-absorbing capacity of technical provisions	R0140	0,00
Loss-absorbing capacity of deferred taxes	R0150	-7.237.784,14
Capital requirement for business operated in accordance with Art. 4 of Directive 2003/41/EC	R0160	
Solvency Capital Requirement excluding capital add-on	R0200	50.664.488,98
Capital add-on already set	R0210	
of which, capital add-ons already set - Article 37 (1) Type a	R0211	
of which, capital add-ons already set - Article 37 (1) Type b	R0212	
of which, capital add-ons already set - Article 37 (1) Type c	R0213	
of which, capital add-ons already set - Article 37 (1) Type d	R0214	
Solvency capital requirement	R0220	50.664.488,98
Other information on SCR		
Capital requirement for duration-based equity risk sub-module	R0400	
Total amount of Notional Solvency Capital Requirements for remaining part	R0410	
Total amount of Notional Solvency Capital Requirements for ring-fenced funds	R0420	0,00
Total amount of Notional Solvency Capital Requirements for matching adjustment portfolios	R0430	0,00
Diversification effects due to RFF nSCR aggregation for article 304	R0440	0,00

Approach to tax rate		C0109
Approach based on average tax rate	R0590	Approach based on average tax rate

		LAC DT
		C0130
LAC DT	R0640	-7.237.784,14
LAC DT justified by reversion of deferred tax liabilities	R0650	0,00
LAC DT justified by reference to probable future taxable economic profit	R0660	-7.237.784,14
LAC DT justified by carry back, current year	R0670	0,00
LAC DT justified by carry back, future years	R0680	0,00
Maximum LAC DT	R0690	-5.790.227,31

Section G

S.28.02.01

Minimum Capital Requirement - Both life and non-life insurance activity

		Non-life activities	Life activities
		MCR(NL, NL) Result	MCR(NL, L)Result
		C0010	C0020
Linear formula component for non-life insurance and reinsurance obligations	R0010	725.245,71	0,00

		Net (of reinsurance/ SPV) best estimate and TP calculated as a whole	Net (of reinsurance) written premiums in the last 12 months	Net (of reinsurance/SPV) best estimate and TP calculated as a whole	Net (of reinsurance) written premiums in the last 12 months
		C0030	C0040	C0050	C0060
Medical expenses and proportional reinsurance	R0020	2.066.138,62	13.364.621,13		
Income protection insurance and proportional reinsurance	R0030				
Workers' compensation insurance and proportional reinsurance	R0040				
Motor vehicle liability insurance and proportional reinsurance	R0050				
Other motor insurance and proportional reinsurance	R0060				
Marine, aviation and transport insurance and proportional reinsurance	R0070				
Fire and other damage to property insurance and proportional reinsurance	R0080				
General liability insurance and proportional reinsurance	R0090				
Credit and suretyship insurance and proportional reinsurance	R0100				
Legal expenses insurance and proportional reinsurance	R0110				
Assistance and proportional reinsurance	R0120				
Miscellaneous financial loss insurance and proportional reinsurance	R0130				
Non-proportional health reinsurance	R0140				
Non-proportional casualty reinsurance	R0150				
Non-proportional marine, aviation and transport reinsurance	R0160				
Non-proportional property reinsurance	R0170				

		Non-life activities	Life activities
		MCR(L, NL) Result	MCR(L, L) Result
		C0070	C0080
Linear formula component for life insurance and reinsurance obligations	R0200	0,00	19.932.579,07

		Net (of reinsurance/SPV) best estimate and TP calculated as a whole	Net (of reinsurance/SPV) total capital at risk	Net (of reinsurance/SPV) best estimate and TP calculated as a whole	Net (of reinsurance/SPV) total capital at risk
		C0090	C0100	C0110	C0120
Obligations with profit participation - guaranteed benefits	R0210			0,00	
Obligations with profit participation - future discretionary benefits	R0220			0,00	
Index-linked and unit-linked obligations	R0230			711.254.182,77	
Other life (re)insurance and health (re)insurance obligations	R0240			2.075.091,04	
Total capital at risk for all life (re)insurance obligations	R0250				21.300.318.399,79

Overall MCR calculation		Value
		C0130
Linear MCR	R0300	20.657.824,78
SCR	R0310	50.664.488,98
MCR cap	R0320	22.799.020,04
MCR floor	R0330	12.666.122,24
Combined MCR	R0340	20.657.824,78
Absolute floor of the MCR	R0350	6.700.000,00
Minimum Capital Requirement	R0400	20.657.824,78

Notional non-life and life MCR calculation		Non-life activities	Life activities
		C0140	C0150
Notional linear MCR	R0500	725.245,71	19.932.579,07
Notional SCR excluding add-on (annual or latest calculation)	R0510	1.778.706,31	48.885.782,67
Notional MCR cap	R0520	800.417,84	21.998.602,20
Notional MCR floor	R0530	444.676,58	12.221.445,67
Notional Combined MCR	R0540	725.245,71	19.932.579,07
Absolute floor of the notional MCR	R0550	2.700.000,00	4.000.000,00
Notional MCR	R0560	2.700.000,00	19.932.579,07

H. Independent Auditors Report

Independent Auditor's Report

To the Board of Directors of Eurolife Limited

Report on the Audit of the relevant elements of the Solvency and Financial Condition Report

Opinion

We have audited the following Solvency II Quantitative Reporting Templates ("QRTs") contained in Annex I to Commission Implementing Regulation (EU) No 2023/895 of 4 April 2023, of Eurolife Limited (the "Company"), prepared as at 31 December 2025:

- S.02.01.02 – Balance sheet
- S.12.01.02 – Life and Health SLT Technical Provisions
- S.17.01.02 – Non-Life Technical Provisions
- S.23.01.01 – Own funds
- S.25.01.21 – Solvency Capital Requirement – for undertakings on Standard Formula
- S.28.02.01 – Minimum Capital Requirement – Both life and non-life insurance activity

The above QRTs are collectively referred to for the remainder of this report as "the relevant QRTs of the Solvency and Financial Condition Report".

In our opinion, the information in the relevant QRTs of the Solvency and Financial Condition Report as at 31 December 2025 is prepared, in all material respects, in accordance with the Insurance and Reinsurance Services and other Related Issues Law of 2016 as amended, the Commission Delegated Regulation (EU) 2015/35 as amended, the relevant EU Commission's Implementing Regulations and the relevant Orders of the Superintendent of Insurance (collectively "the Framework").

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (ISAs). Our responsibilities under those standards are further described in the *Auditor's Responsibilities for the Audit of the relevant QRTs of the Solvency and Financial Condition Report* section of our report. We are independent of the Company in accordance with the *International Ethics Standards Board for Accountants' International Code of Ethics for Professional Accountants (including International Independence Standards) (IESBA Code)* together with the ethical requirements that are relevant to our audit of the relevant QRTs of the Solvency and Financial Condition Report in Cyprus, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the IESBA Code. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Emphasis of Matter

We draw attention to the 'Valuation for solvency purposes', the 'Capital management' and other relevant disclosures sections of the Solvency and Financial Condition Report, which describe the basis of preparation. The Solvency and Financial Condition Report is prepared in compliance with the Framework, and therefore in accordance with a special purpose financial reporting framework. As a result, the Solvency and Financial Condition Report may not be suitable for another purpose. Our opinion is not modified in respect of this matter.

We draw attention to the 'Capital management' section of the Solvency and Financial Condition Report and specifically to paragraph 'E.4 Other' which describes the reasons for the reissuance of the Solvency and Financial Condition Report of the Company as at 31 December 2025 subsequent to its original submission on 3 April 2026 and its initial reissuance on 13 August 2026 to provide enhanced disclosures in relation to this matter. Our opinion is not modified in respect of this matter.

Other information

The Board of Directors is responsible for the Other information. The Other information comprises certain narrative sections and certain QRTs of the Solvency and Financial Condition Report as listed below:

Narrative sections:

- Business and performance
- Valuation for solvency purposes
- Capital management

QRTs (contained in Annex I to Commission Implementing Regulation (EU) No 2023/895 of 4 April 2023):

- S.05.01.02 – Premiums, claims and expenses by line of business
- S.19.01.21 – Non-Life insurance claims

Our opinion on the relevant QRTs of the Solvency and Financial Condition Report does not cover the Other information listed above and we do not express any form of assurance conclusion thereon.

In connection with our audit of the Solvency and Financial Condition Report, our responsibility is to read the Other information and, in doing so, consider whether the Other information is materially inconsistent with the relevant elements of the Solvency and Financial Condition Report, or our knowledge obtained in the audit, or otherwise appears to be materially misstated. If, based on the work we have performed, we conclude that there is a material misstatement of this Other information, we are required to report that fact. We have nothing to report in this regard.

Responsibilities of the Board of Directors for the Solvency and Financial Condition Report

The Board of Directors is responsible for the preparation of the Solvency and Financial Condition Report in accordance with the Framework.

The Board of Directors is also responsible for such internal control as the Board of Directors determines is necessary to enable the preparation of a Solvency and Financial Condition Report that is free from material misstatement, whether due to fraud or error.

In preparing the Solvency and Financial Condition Report, the Board of Directors is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors is responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the relevant QRTs of the Solvency and Financial Condition Report

Our objectives are to obtain reasonable assurance about whether the relevant QRTs of the Solvency and Financial Condition Report are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but it is not a guarantee that an audit conducted in accordance with ISAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the Solvency and Financial Condition Report.

As part of an audit in accordance with ISAs, we exercise professional judgement and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the relevant QRTs of the Solvency and Financial Condition Report, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.

- Evaluate the appropriateness of the basis of preparation used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Solvency and Financial Condition Report or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.

We communicate with the Board of Directors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Other Matter

Our report is intended solely for the Board of Directors of the Company and should not be used by any other parties. We do not, in giving this opinion, accept or assume responsibility for any other purpose or to any other person to whose knowledge this report may come to.

PricewaterhouseCoopers

PricewaterhouseCoopers Limited
Certified Public Accountants and Registered Auditors

PwC Central, 43 Demostheni Severi Avenue
CY-1080 Nicosia Cyprus

7 September 2026

PricewaterhouseCoopers Ltd is a private company registered in Cyprus (Reg. No.143594). Its registered office is at PwC Central, 43 Demostheni Severi Avenue, CY-1080 Nicosia. A list of the company's directors, including for individuals the present and former (if any) name and surname and nationality, if not Cypriot and for legal entities the corporate name, is kept by the Secretary of the company at its registered office. PwC refers to the Cyprus member firm, PricewaterhouseCoopers Ltd and may sometimes refer to the PwC network. Each member firm is a separate legal entity. Please see www.pwc.com/structure for further details.